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ABSTRACT 
 
A MICROFLUIDIC APPROACH FOR INVESTIGATING THE ROLE OF 
INTRATHROMBUS TRANSPORT IN THROMBOSIS AND HEMOSTASIS 
 
Ryan W. Muthard 
Scott L. Diamond 
Biological and physical factors interact to modulate blood response in a wounded 
vessel, resulting in a hemostatic clot or an occlusive thrombus.  Wall shear stress (w) and 
pressure differential (P) across the wound from the lumen to the extravascular 
compartment may impact hemostasis.  This thesis describes the design of a microfluidic 
device capable of flowing human blood over a side channel plugged with collagen (± 
tissue factor) while independently controlling ΔP and w.  Using this device we were able 
to investigate the impact of physiologic hemodynamics on the growth and architecture of 
human blood clots.  Our results revealed that both wall shear rate and the transthrombus 
pressure gradient govern clot development leading to the formation of two distinct 
intrathrombus regions; a core of highly-activated platelets and fibrin covered by a shell of 
less-activated platelets.  These regions mimic the activation gradients of clots formed in 
vivo.  We demonstrated that core development was dependent on the transthrombus 
pressure gradient restricting thrombin localization while shell development was 
dependent on wall shear rates.  We also found that fibrin polymerization inhibited 
thrombin activity at both arterial and venous shear rates. However, the mechanism of this 
inhibition is shear dependent. At venous shears thrombin activity is inhibited by ’-
fibrin(ogen) binding. While at arterial and pathological shear rates the clot forms a more 
dense structure leading to physical trapping of thrombin independent of ’-fibrin(ogen) 
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binding. Taken together our data supports a model where clot architecture is maintained 
under various conditions by shear-specific thrombin inhibition mechanisms.  Lastly, we 
demonstrated that the prevailing hemodynamics dilute ADP and thromboxane to regulate 
platelet contractility, a newly defined flow sensing mechanism to regulate clot function.   
The field of in vitro hemostasis and thrombosis research has lacked an assay 
capable of independently studying the effects of ΔP and local w on clot development and 
function.  Our microfluidic device bridges this gap, while providing new insights into the 
mechanisms of hemostasis and thrombosis, where hemostatic clot development must 
balance both thrombotic and hemorrhagic risks in order to rapidly and controllably cease 
bleeding. 
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Chapter 1 : Introduction 
1.1 Hemostasis 
1.1.1 Platelets 
Platelets are anucleate cells that are responsible for hemostasis, or the cessation of 
bleeding.  The process in which platelets are produced is termed megakaryopoiesis.  In 
this process, megakaryocytes are derived from hematopoietic stem cells primarily within 
the bone marrow.  Following proliferation and differentiation, megakaryocytes go 
through a maturation process that ends with the release of new platelets into the 
circulation [1].   Healthy whole blood typically contains 150,000-400,000 platelets per 
microliter [2].  Human platelets in an unactivated state are typically 2-3 µm in diameter 
and have a disk shape [3].  In the presence of platelet agonists, such as collagen or 
thrombin, platelets become activated through agonist specific surface receptors.  
Activation causes an increase in intracellular calcium resulting in a conformational 
change in the platelet cytoskeleton due to interactions between myosin II and actin 
filaments [4].   In addition to shape change, platelet activation also initiates secretion of 
soluble agonists such as adenosine diphosphate (ADP) and thromboxane A2 (TXA2) [5].  
This autocrinic process is important for the recruitment of additional platelets and the 
stabilization of deposited platelets during the formation of a stable clot.  The timeline of 
platelet activation, shape change, and agonist secretion have been studied extensively in 
both single platelet and clot formation. 
In terms of hemostatic clot growth, initial platelet adhesion and subsequent 
aggregation are required for platelet plug formation.  Under flow conditions, platelets 
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initially adhere to the site of injury by binding to collagen and/or von Willebrand factor 
(vWF).  The initial adhesion of platelets is mediated through receptors α2β1 and GPVI 
for collagen and αIIbβ3 and GPIb for vWF [6].  Following firm adhesion and platelet 
activation, secretion of ADP and TXA2 help recruit additional platelets to the site of 
injury.  The release of these agonist also help activate integrin αIIbβ3, a critical integrin 
for platelet aggregation.  The conformational change of αIIbβ3 to its active state 
facilitates the binding of fibrinogen and vWF.  These proteins have multiple binding sites 
for activated αIIbβ3 which enable more than one platelet to bind the same protein.  This 
stage is known as aggregation and is vital for the extension of the clot and the cessation 
of bleeding [7].  While platelets are aggregating, the local accumulation of agonists 
increase the activation level of firmly adhered platelets.  This increase in activation 
results in cytoskeleton rearrangement into a conformational state that anchors adjoining 
platelets tightly together.  The contraction of both single platelets and platelets within 
regions of high activation securely fastens the clot to the injury site.  This prevents 
additional bleeding by fortifying the clot, thus preventing it from being torn from the 
surface. 
Another important aspect of platelets is their ability to provide a surface for 
protein binding.  When platelets are activated, the surface of the platelet becomes 
negatively charged due to the phospholipids that are transferred from the inner membrane 
to the outer membrane [8].  This charge is important for the association of several 
proteins that are required for thrombin generation.  This step is known as coagulation. 
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1.1.2 Blood Coagulation 
Blood coagulation, another important branch of hemostasis, is required for the 
generation of thrombin and the formation of fibrin.  In this process, proteins known as 
coagulation factors work in series and parallel to converge on a common pathway in 
order to cleave prothrombin into thrombin.  The two paths in the coagulation cascade that 
lead to the common pathway are the intrinsic and extrinsic pathways.  Both of these 
pathways lead to the generation of activated factor X (Factor Xa) [9, 10].   
The intrinsic pathway, also known as the contact pathway, is initiated with a 
negatively charged surface.  At the injury site, activated platelets or damaged smooth 
muscle cells/endothelial cells provide a negatively charged phospholipid surface that 
converts Factor XII to Factor XIIa.  This activation step then facilitates the cleavage of 
Factor XI to Factor XIa.  Following these events, the intrinsic tenase complex is formed 
by Factor IXa and its cofactor, Factor VIIIa.  This complex rapidly cleaves Factor X to 
Factor Xa [9].  If any of these factors are deficient or are defective, the production of 
thrombin via the intrinsic pathway is significantly hindered.  Examples of this include 
hemophilia A, hemophilia B, and hemophilia C, diseases in which blood is deficient in or 
contain defective factors VIII, IX, and XI respectively [11].  While these disorders often 
present with a bleeding phenotype if they are severe, the extrinsic pathway can often 
alleviate some of these issues. 
The extrinsic pathway, also known as the tissue factor pathway, is well regarded 
as the dominating pathway for thrombin generation in vivo.  The exposure of tissue factor 
(TF) on the cell surface initiates the extrinsic pathway at the site of vascular injury.  
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Circulating Factor VII associates with the cell bound TF and is then activated by one of 
several coagulation proteases (IIa, Xa, IXa, XIIa, VIIa-TF).  Once activated, the extrinsic 
tenase facilitates a burst of thrombin production by rapidly cleaving Factor X to Factor 
Xa.  In addition to Factor Xa generation, the extrinsic tenase also facilitates the cleavage 
of Factor IX to Factor IXa.  This cleavage helps bypass the requirement of intrinsic 
coagulation Factors XIIa and XIa [10]. 
The common pathway requires Factor Xa which is generated by either or both the 
intrinsic and extrinsic tenase.  Factor Xa associates with the activated protein cofactor, 
Factor Va on a negatively charged membrane surface.  This complex is known as the 
prothrombinase complex.  Following assembly, the prothrombinase can efficiently cleave 
prothrombin into thrombin [12].  The generation of thrombin facilitates the enzymatic 
cleavage of fibrinogen into fibrin monomer.  As fibrin monomer is produced, it then 
polymerizes both laterally and longitudinally to form fibers which are important for 
additional clot strength and support [13].  The formation of fibrin is the primary goal of 
the coagulation cascade and is critical for stabilizing the developing clot and ceasing 
bleeding. 
1.1.3 Vasculature 
The vasculature also plays an important role in hemostasis.  During vessel injury, 
smooth muscle cells contract to limit blood flow through the injured vessel.  This 
response is mediated by endothelial cells and platelets near the site of injury.  These cells 
release stimuli such as endothelin and TXA2 to induce vessel constriction [14].  The drop 
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in flow through the vessel prevents unnecessary blood loss while maintaining a supply of 
platelets and coagulation proteins to facilitate proper hemostasis. 
1.2 Thrombosis 
An important part of the hemostatic process is the regulation of the platelet and 
coagulation response.  If either one of these regulatory responses are dysfunctional, clot 
growth and/or thrombin generation may result in thrombosis, the prevention of blood 
flow through a vessel by an occlusive thrombus.  There are two types of thrombosis, one 
which occurs within a vein (venous thrombosis) and one which occurs within an artery 
(arterial thrombosis).  One of the most prevalent forms of venous thrombosis is deep vein 
thrombosis (DVT).  Risk factors for DVT typically include immobilization, surgery, or 
cancer [15].  Prophylaxis is often effective and is typically achieved with anticoagulant 
drugs such as heparin or vitamin K antagonists [16].  Arterial thrombosis is similar to 
venous thrombosis with the distinction that the occlusive event occurs within an artery.  
The primary example of arterial thrombosis is myocardial infarction or a heart attack.  
This is an event which prevents blood flow to a part of the heart.  Patients experiencing 
myocardial infarctions usually present with atherosclerosis, a chronic disease associated 
with a plaque buildup in the arteries [17].  The accumulation of plaque in the arterial 
blood vessel wall can lead to a lesion within a stenosed vessel that will eventually 
rupture.  At the point of rupture, the narrow channel quickly becomes occluded with 
platelets and fibrin, preventing blood flow to the heart.  Typical prophylaxis for 
myocardial infarctions include antiplatelet drugs, stents, and bypass surgery [18, 19]. 
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In both conditions, one of the major concerns is that the occlusive clot may 
embolize, an event known as thromboembolism.  This type of event is caused by a clot 
that breaks free from an upstream injury site and eventually becomes lodged in a 
downstream vessel.  Thromboembolism is particular concerning in patients with DVT or 
myocardial infarction.  If the thrombus embolizes and travels to the lungs or to the brain, 
the patient is at risk for pulmonary embolism or stroke respectively.  Both of these 
conditions can be fatal.  Understanding the physical and biochemical properties that 
regulate thrombosis and/or thromboembolism may lead to improved patient care and 
outcome, making this field of study critical in the research community. 
1.3 Transport in Hemostasis 
1.3.1 Hemodynamics 
Hemodynamics is the study of circulation and the physical forces that govern 
blood flow.  These forces vary throughout the vasculature, creating diverse environments 
in which platelets must respond and thrombin must be generated in order to achieve 
proper hemostasis.  Blood is composed of red blood cells, platelets, white blood cells, and 
plasma.  In a healthy individual, the plasma portion of blood normally makes up 55-60% 
of the total volume.  The cells and plasma proteins in blood give it characteristics that 
make it a non-Newtonian fluid.  In particular, blood is a shear-thinning fluid.  As shear 
rates increases, the viscosity of blood is decreases.  For simplicity, blood is often treated 
as a Newtonian fluid where viscosity is constant for all shear rates.  This assumption is 
valid when shear rates are greater than 50 s-1 [20].  Wall shear rate is an important term in 
hemodynamics because it is dependent on the blood velocity and the vessel diameter.  
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The Navier-Stokes equation describes the velocity field for a Newtonian fluid at motion 
in a cylindrical vessel: 
Eqn. 1-1         𝜌 (
𝜕𝑣𝑧
𝜕𝑡
+ 𝑣𝑟
𝜕𝑣𝑧
𝜕𝑟
+
𝑣𝜃
𝑟
𝜕𝑣𝑧
𝜕𝜃
+ 𝑣𝑧
𝜕𝑣𝑧
𝜕𝑧
) = −∇𝑝 + 𝜇 (
1
𝑟
𝜕
𝜕𝑟
(𝑟
𝜕𝑣𝑧
𝜕𝑟
) +
1
𝑟2
𝜕2𝑣𝑧
𝜕𝜃2
+
𝜕2𝑣𝑧
𝜕𝑧2
) 
where 𝜌 is the fluid density, 𝑣𝑧 is the fluid velocity in the flow direction, 𝑣𝑟 is the fluid 
velocity in the radial direction, 𝑣𝜃 is the fluid velocity in the tangential direction, 𝑝 is the 
pressure, and  𝜇 is the dynamic viscosity.   
In the case of blood flow, the velocity of the blood through a given vessel 
diameter is driven by the pressure drop along the length of the vessel.  An exact solution 
for Eqn. 1-1 can be derived to determine the mean blood velocity in terms of vessel 
pressure drop.  The first requirement is that the flow must be fully developed, meaning 
that velocity is not changing in the flow direction (
𝜕𝑣𝑧
𝜕𝑧
= 0).  This assumption holds true 
due to the laminar characteristics of blood flow.  Laminar flows are more predictable and 
have more of a dependence on viscous force than turbulent flows, which depend more on 
inertial forces.  When flow is laminar the entrance length containing velocity changes in 
the flow direction is on the order of the vessel radius [21].  This is typically much smaller 
than the length of the vessel.  The second requirement is that the flow is steady.  This 
means that the velocity field is not changing with time (
𝜕
𝜕𝑡
= 0).  This assumption is valid 
in smaller vessels such as the arterioles and venules where the pulsatility of the 
circulatory system is minimized [22].  In larger vessels such as the aorta or inferior vena 
cava, the pumping of the heart results in pulsatile flow due to the transient pressure 
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supply.  The final assumptions are that the radial (𝑣𝑟 = 0) and tangential components 
(𝑣𝜃 = 0) of the fluid velocity are zero and flow is axisymmetric (
𝜕
𝜕𝜃
= 0).  These 
assumptions are valid for unidirectional flow, where there is no rotational component of 
the velocity.  The laminar flow characteristics within smaller blood vessels minimizes the 
rotational component of velocity.  Alternatively, this assumption fails in flows near the 
heart and at bifurcations where flow characteristics begin to transition from the laminar 
regime to the turbulent regime.  In small vessels such as arterioles and venules, blood 
velocity can be calculated with the Hagen-Poiseuille equation: 
Eqn. 1-2   ∆𝑃 =
32𝜇𝐿𝑣
𝐷2
     
where ∆𝑃 is the pressure difference from the beginning to the end of the vessel, 𝜇 is the 
dynamic viscosity, 𝐿 is the vessel length, 𝑣 is the mean blood velocity, and 𝐷 is the 
vessel diameter.  In this equation, the blood velocity depends on the diameter, length and 
pressure drop in the vessel.  Lumen pressure and diameter vary in both the arterial and 
venous circulation.  Typically, blood velocity is higher in the arterial circulation than the 
venous circulation leading to higher shear rates in the arterial vessels rather than the 
venous vessels.  The increase in shear is caused by the increased pressure drop.  
Literature values for arterial shear rates normally are given in the range of 700-2000 s-1 
while venous shear rates are usually around 200 s-1 [23].  In pathophysiology, narrowed 
or stenosed vessels can experience shear rates in excess of 100,000 s-1 [24]. 
While shear rate is important in terms of the convective delivery of platelets to the 
injury site, the pressure gradient between the lumen and the interstitial space drives 
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bleeding out of the vessel.  In physiology, these pressure gradients can vary depending on 
the location of the injured vessel.  For example, capillary blood pressure can range from 
25 mm Hg to 90 mm Hg between the head and feet due to gravity [25].  Depending on 
lumen diameter, arterioles usually range from 50-85 mm Hg while venules range from 
20-30 mm Hg [23].  The interstitial pressure is not as sensitive, usually ranging from -2 
mm Hg to 10 mm Hg [26].  This places the range of pressure gradients between the 
lumen and extravascular space roughly between 10-85 mm Hg.  In order to cease 
bleeding, clots must prevent these pressure gradients from driving blood loss.  They 
accomplish this by tightly packing together to create a porous media that increases the 
resistance to flow. 
1.3.2 Porous Media Transport 
Porous materials are composed of a solid matrix with a pore or void space filled 
with fluid.  These materials are typically characterized by their porosity and permeability.  
Porosity is defined as the ratio of empty or void volume divided by the total volume of 
both the fluid and solid.  Depending on the structure of the solid matrix, porosity can 
range from 0 to 1.  In vivo clot porosity has been calculated experimentally and is 
typically within a range between 0.4-0.7 depending on the location of the measurement 
within the clot [27].  The other characteristic used to define porous media is permeability.  
The permeability of a porous material is defined by the material’s ability to permit fluid 
flow through the structure.  Permeability has been estimated to be within the range of 10-
11 – 10-13 cm2 for compacted coronary thrombi [28]. 
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Porosity and permeability can be used to predict protein and fluid transport within 
and through blood clots.  Protein transport is influenced by the protein’s diffusivity 
within the clot and the fluid velocity through clot.  The diffusion coefficient, or the 
diffusivity for the molecule or protein of interest, is a constant used to describe the 
proportionality between the molar flux and the concentration gradient of the species.  In 
porous media, diffusivity of a protein or molecule can be reduced.  This is determined by 
the effective diffusivity which is dependent on the material porosity, the free diffusion 
coefficient, the tortuosity of the material and the constrictivity.  The other mode of 
transport within clots is the fluid velocity, which can be predicted by Darcy’s Law: 
Eqn. 1-3              𝑄 =
𝜅𝐴∆𝑃
𝜇𝐿
 
where 𝑄 is the volumetric flow rate, 𝜅 is the material’s permeability, 𝐴 is the cross-
sectional area to flow, ∆𝑃 is the pressure drop across the media, 𝜇 is the dynamic 
viscosity of the fluid, and 𝐿 is the length in which the pressure drop is achieved.  Darcy’s 
Law was derived from the Navier-Stokes equation (Eqn 1-1) by assuming that the flow 
through the clot is an incompressible, creeping flow and the porous media is isotropic.  In 
a creeping flow, inertial forces are small compared to the viscous forces and 
𝐷(𝜌𝑣𝑖)
𝐷𝑡
~0.  
This assumptions is valid due to the slow flow velocities and small length scales for 
porous media transport in clots.   
 While both advection and diffusion can drive protein transport, it is often 
beneficial to understand if one of these forces dominates the transport of protein in 
porous media.  This can be characterized by the Péclet number: 
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Eqn. 1-4              𝑃𝑒 =
𝐿𝑈
𝐷
 
where 𝐿 is the characteristic length, 𝑈 is the velocity, and 𝐷 is the diffusion coefficient.  
The Péclet number is a dimensionless number that compares the ratio of advective 
transport to the diffusive transport.  A low Péclet number (Pe<<1) is representative of 
transport that is dominated by diffusion while a high Péclet number (Pe>>1) is 
representative of transport that is dominated by advection forces.  The permeability, 
porosity, and the resulting Péclet number are important parameters needed to better 
understand how protein and agonist are transported within clots as they develop under 
flow.  New methods are required to accurately measure these parameters under 
hemodynamic conditions and at the micron scale. 
1.4 Experimental Techniques for Hemostasis Under Physiologic Conditions 
With the advances in technology, hemostasis measurements under physiologic 
conditions have become more reliable both in vitro and in vivo.  Two in vivo methods that 
have become the standard for hemostatic measurements are the tail bleed assay and the 
mouse cremaster laser injury model [27, 29].  The tail bleeding assay has existed for over 
60 years [30].  This assay focuses on the time that it takes for bleeding to cease from the 
tip of a mouse tail that has been amputated or incised.  More recently, the mouse 
cremaster laser injury model has been utilized [27].  This model facilitates the 
microscopic observation of platelet and coagulation function as they work together to 
form a stable clot on the injured vessel wall.  In both of these injury models, the 
hemostatic response is measured by the platelets, coagulation, and vasculatures ability to 
cease bleeding under physiologic conditions.   
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In vitro models of hemostasis have drastically improved with the development of 
both photo and soft lithography techniques.  These techniques have facilitated the 
production of geometrically controllable chips with micron scale resolution.  The 
channels within the chips, also known as microfluidic devices, are designed to control 
and manipulate small volumes of fluid.  This makes them ideal for studying 
hemodynamics.  Previous work has pioneered the use of blood and study of thrombus 
formation within microfluidic channels [31].  In these studies, the wall shear rate was 
controlled to better understand the significance of these rates on thrombus formation.  
The ability to control hemodynamic conditions and localize thrombus formation, for 
microscopic imaging, makes microfluidics an ideal system for characterizing the role that 
physical forces have on clot development. 
While these models all have their strengths and weaknesses, we were motivated to 
design and validate a new microfluidic assay to independently control both wall shear 
rate and transthrombus pressure gradients.  The merging of previous microfluidic 
techniques with control of the hemodynamics represented in the laser injury model would 
provide us with a platform to understand the role of protein transport within clots formed 
under physiologic conditions.  Insights into the transport mechanisms that are utilized by 
clots formed under hemodynamic conditions will be crucial for improved drug design and 
treatment of thrombotic events. 
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Chapter 2 : Side view thrombosis microfluidic device with controllable wall shear 
rate and transthrombus pressure gradient 
2.1 Introduction 
At the onset of vessel injury, collagen and subendothelial matrix become exposed 
to flowing blood.  Hemostasis is maintained by platelet adhesion and aggregation at the 
site of injury [32], along with thrombin production triggered by extravascular tissue 
factor. The local physical and biological stimuli present during this development play a 
critical role in the final clot structure and function.  One important physical parameter 
that has long been recognized is the prevailing wall shear stress (w) [33], with the venous 
system having lower wall shear stresses than the arterial system [23].  Often absent in the 
design of in vitro models is the transthrombus pressure gradient (ΔP) that exists between 
the intraluminal space and the interstitial compartment of vascularized tissue.  
Incorporating this feature into thrombus development could quickly change the profile of 
soluble species, resulting in altered clot structures. 
In recent years, several in vivo studies have demonstrated the importance of 
interstitial pressure and flow on angiogenesis [34, 35].  This research has benefited from 
the ability to control physical factors such as pressure gradients and shear rates using in 
vitro microfluidic devices.  Previous work illustrated control of these parameters but at 
levels not representative of the arterial vasculature [36].  Others have shown control of w 
or ΔP, but decoupling their dependence at high and low shear stress is a difficult task [31, 
37].  Independently controlling both pressure gradients and wall shear stresses at arterial 
or venous conditions would provide an important understanding of hemostasis in blood 
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vessel microenvironments.  There have not been any devices that incorporate this level of 
control. 
We were able to design and validate a microfluidic device capable of 
independently controlling the wall shear stress and trans-scaffold pressure gradient.  
Localization of collagen ± tissue factor (TF) in the scaffold region of the device allowed 
side view imaging of thrombosis under controlled transthrombus pressure drops.  At 
arterial wall shear stress, small increases in transthrombus pressure gradients significantly 
reduced average platelet and platelet/fibrin clot heights.  Similarly, the periphery and 
quantity of thrombin within the clot was reduced in the presence of increased 
transthrombus permeation.  Permeability measurements were obtained under flow by 
utilizing dye pulsing.  The collagen scaffold permeability was validated with previous 
literature values and new measurements of platelet and platelet/fibrin clot permeability 
were calculated at various pressure drops.  We demonstrate the ability to independently 
control trans-scaffold pressure gradients and wall shear stresses for studying the 
permeation effects and rates on or through thrombi. 
2.2 Materials and Methods 
2.2.1 Device Fabrication and Design 
Polydimethylsiloxane (PDMS) (Ellsworth Adhesives) microfluidic devices were 
fabricated using previously described soft lithography techniques [38].  In brief, 
photolithography was used to preferentially pattern negative photoresist (KMPR 1050, 
MicroChem Corp.) on a silicon wafer (D = 100 mm, WRS Materials).  The photoresist 
was spun to a height of 60 μm then soft baked for 20 min.  Following baking, the 
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substrate was placed beneath a photomask and exposed to UV illumination.  Prior to 
development (AZ® 300 MIF, AZ Electronic Materials USA Corp.), the substrate was 
baked for 4 minutes at 100 oC.  PDMS, with a base to curing agent ratio of 10:1, was then 
molded on the substrate for 2 hr at 80oC.  Inlet/outlet and pressure ports (Figure 2-1A) 
were cut out using 0.75 and 0.5 mm I.D. corers (Harris Uni-Core™, Ted Pella, Inc.), 
respectively.  PDMS-tubing (0.020” ID x 0.060” OD, Cole-Parmer) connections were 
made via 90o, 23 gauge x 1/2” length blunt needles (Small Parts). 
The device was designed with a primary channel (60 μm high x 250 μm wide) 
connected to two inlets (upstream, downstream), two outlets (scaffold, channel), and 
three pressure ports (P1, P2, P3).  The upstream inlet was used for fluid that will come in 
direct contact with the scaffold while the downstream inlet, prior to the compressed 
channel (200 μm wide), was added to create resistance to flow upstream (Figure 2-1A).  
The added resistance caused increased pressure due to the constant volume syringe 
pumps.  Two pressure ports were added upstream (P2) and downstream (P1) of the 
scaffold region to accurately measure the pressure at the scaffold-channel interface.  An 
additional pressure port (P3) was placed next to the scaffold outlet port to determine the 
pressure drop across the region.  The scaffold was designed with an array of posts (D = 
50 μm) spaced 20 μm apart with a narrowed opening from L = 250 μm at the interface to 
L=50 μm at the exit (Figure 2-1B).  The posts positions were ideal for uniformly loading 
collagen fibers and the compressed exit forced the majority of the pressure drop across 
the scaffold rather than the exiting channel.  Post arrays were placed surrounding each of 
the channel setups to support the negative pressure due to vacuum sealing to glass slides 
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(Figure 2-1C).  All of the design features in this device made it possible to monitor and 
control the pressure gradients across the scaffold, while maintaining constant wall shear 
stress at the interface. 
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Figure 2-1 A microfluidic device with controllable trans-scaffold pressure 
gradients. 
Syringe pump inlet Q1 provided a constant volume flow that exited through the 
downstream outlet or transversed the collagen region towards the outlet monitored by P3 
(A).   The main flow channel (H=60 μm, W=250 μm) provided a collagen-fluid flow 
interface between pressure sensors P2 and P1 (B). A LabVIEW control panel interpreted 
the pressure measurements (P1, P2, P3) and proportionately controlled a constant volume 
syringe pump (Q2) to maintain constant pressure gradients across the collagen region.  
Prior to use, the PDMS microfluidic device was vacuum sealed to a glass slide and 
connections between the tubing and device were made via 90o, 23-gauge blunt needle tips 
(C). 
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2.2.2 Device Operation 
Devices were vacuum sealed to Sigmacote® (Sigma-Aldrich) treated glass slides 
and channels were coated with a 10% BSA solution for 30 min.  Polymerized fibrillar 
collagen was prepared overnight by incubating (37 oC) an 8:1:1 ratio of collagen (3 
mg/ml monomeric, human Type I) (Vitrocol, Advanced BioMatrix, Inc.), 10x PBS, and 
0.09M NaOH respectively.  Tissue factor liposomes were prepared as previously 
described [38, 39].  Briefly, biotinylated anti-collagen (4 μg/ml, Abcam) and streptavidin 
(10 μg/ml, Sigma-Aldrich) were mixed subsequently in a 1:10 volumetric ratio with 
polymerized collagen.  Following a 5 min room temperature incubation for each, 
biotinylated/TF liposomes (79:20:1, L-α-phosphatidylcholine (PC):L-α-
phosphatidylserine (PS):biotinylated phosphatidylethanolamine (bPE), Avanti Polar 
Lipids) were mixed in a 1:20 ratio by volume with the polymerized collagen/biotinylated 
anti-collagen/streptavidin mixture.  The solution was incubated for an additional 10 
minutes at room temperature.  Device scaffolds were then loaded by pulling 2.5 μL of 
polymerized collagen (±TF liposomes) through pressure ports P1 and P2 out of the 
scaffold region exit.  Immediately following loading, Ca2+ buffer (5mM) was rinsed 
through the channels to remove any collagen outside of the scaffold.  Devices were setup 
on a slide holder for imaging using a CCD camera (ORCA-ER, Hamamatsu) on an 
inverted microscope (IX81, Olympus America Inc.). 
The loaded channel was then connected to the three pressure sensors (P1, P2, P3) 
and the upstream and downstream syringe pumps as previously discussed.  The flow rate 
from the upstream pump (PHD Ultra, Harvard Apparatus) provided a constant initial wall 
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shear stress (33.9 dyne/cm2) at the scaffold by setting a constant flow rate (13 μl/min).  
Pressure transducers (Honeywell Sensing and Control) connected at the P1, P2, and P3 
ports transmitted analog voltage signals to a data acquisition device (NI USB-6210, 
National Instruments) that was used to process the measurements in LabVIEW (National 
Instruments, Figure 2-2).  The flow rate from the downstream pump (PHD 2000, 
Harvard Apparatus) was controlled proportionately according to the real-time pressure 
measurements (Figure 2-3 and Figure 2-4).  This control allowed the device to maintain 
constant pressure drop across the scaffold throughout the experiment. 
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Figure 2-2 A LabVIEW program to measure and control microfluidic pressure 
gradients. 
A user interface was developed to monitor instantaneous pressure measurements inside of 
the microfluidic channel at three independent pressure sensors.  The pressure transducers 
outputted voltage signals that were then converted into pressure.  The pressures were 
monitored and controlled proportionally by a proportional gain constant (Kp) that 
produced a resulting flow rate required to maintain the pressure gradient set point.  The 
interface continuously displayed the resulting voltage, pressure, and flow rate (A).  The 
underlying block diagram illustrates the voltage to pressure signal conversion and the 
proportionate controller used to calculate the required buffer infusion flow rate (B). 
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Figure 2-3 A customized LabVIEW interface for controlling syringe pump flow 
rates to maintain a pressure gradient set point.   
This interface directly controls a Harvard Apparatus PHD 2000 syringe pump allowing 
computer input of the infusion rate, refill rate, syringe diameter, pumping direction, and 
on/off.  For the purpose of controlling microfluidic pressure gradients, the interface was 
supplemented with inputs for pressure set point, proportional gain, output high, and 
output low.  Prior to imaging under flow, this interface was initiated (Run/Stop) and 
device pressure gradients were stabilized at the desired set point. 
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Figure 2-4 A LabVIEW block diagram utilized to control a Harvard Apparatus 
PHD 2000 syringe pump.   
This block diagram was supplemented with code to control the output infusion rate based 
on an externally designed proportional controller interface using instantaneous 
microfluidic pressure measurements.  The external program measures pressure and 
calculates an adjusted flow rate necessary to proportionally control the pressure gradient 
at the desired set point.  The flow rate is passed to this interface which continuously 
updates the pump infusion rate every 0.5 s, allowing the microfluidic pressure gradients 
to remain constant. 
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2.2.3 Device Validation 
Pressure transducers were calibrated between 0-1 psig in LabVIEW using 
atmospheric pressure and 27.7 inches of H2O respectively.  The device was validated by 
measuring the permeability of collagen loaded in the scaffold.  An injection valve (V-
450, IDEX Health & Science LLC) was placed between the syringe pump and the 
microfluidic channel (Q1) to produce a controlled pulse under constant flow.  The average 
velocity through the scaffold was measured by pulsing ~25 µL of sulforhodamine 101 
acid chloride (Texas Red, Sigma-Aldrich) in 5 mM Ca2+ buffer through the channel and 
monitoring dye FI at the inlet and outlet of the collagen scaffold.  Measuring the average 
velocity through the collagen allowed permeability to be calculated over the complex 
domain using COMSOL Multiphysics software.  The resulting collagen permeability was 
validated by comparisons to previously determined literature values [41, 42].  The 
permeability of platelet and platelet/fibrin deposited layers could then be measured using 
similar techniques by pulsing ~25 µL of fluorescein isothiocyanate (FITC, Sigma-
Aldrich) in Ca2+ buffer (5 mM) following 10 minutes of whole blood flow (1130 s-1) at a 
range of physiologic pressure drops [25, 26]. 
2.2.4 Blood Collection 
Blood draws were in accordance with the University of Pennsylvania’s IRB and 
all healthy volunteers were self reported as alcohol and medication free.  Human blood 
was collected from donors directly into anti-coagulant via venipuncture.  Studies 
examining the absence of thrombin were completed with 100 μM of the anti-coagulant 
Phe-Pro-Arg-chloromethylketone (PPACK, Haematologic Technologies Inc.) and 1 
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μg/ml of a fluorescently conjugated anti-CD41 monoclonal antibody (Abd Serotec).  
Uninhibited thrombin studies were completed in 40 μg/ml of the anti-coagulant corn 
trypsin inhibitor (CTI, Haematologic Technologies Inc.) and 0.125 µg/ml of a PE-
conjugated anti-CD61 antibody (Becton Dickinson Biosciences).  CTI-treated blood was 
also supplemented with 5 μg/ml of a thrombin sensitive antibody (ThS-Ab) for thrombin 
localization studies [43], 0.0625 μg/ml of a PE-conjugated anti-CD62P antibody (Becton 
Dickinson Biosciences) for P-selectin studies, and 0.5 µg/ml of a fluorescently 
conjugated anti-fibrin antibody (gift from the M. Poncz, Children’s Hospital of 
Philadelphia) for fibrin localization studies [44, 45]. 
2.2.5 Finite Element Analysis 
During the design phase of the microfluidic fabrication, COMSOL Multiphysics 
was used to predict the localization of collagen in the scaffold.  The entire structure was 
modeled and the pressure ports were a source of collagen (C=1) while the remainder of 
the ports with exception to the scaffold exit were a source of 5 mM Ca2+ (C=0).  The 
solution was pulled through the scaffold exit at a velocity (1 mL/min) similar to slowly 
pulling with a 1 mL syringe.  Velocity profiles and concentration localization plots were 
used to predict the best suited scaffold design.  COMSOL was also used to calculate clot 
wall shear stress on experimentally defined clot structures at two minute time intervals.  
Three-dimensional simulations were modeled using experimental clot structures in a 250 
µm wide x 60 µm high channel.  The inlet flow rate was set to 13 µL/min and the middle 
60% of the clot surface was averaged over 100 equal spaced lines scans for each time 
dependent structure.  In an independent measurement, COMSOL was used to calculate 
25 
 
permeability [45].  Briefly, the pulsed dye buffer was modeled using the stationary 
Navier-Stokes equation for laminar flow.  The collagen, platelet deposit, and 
platelet/fibrin structures were simulated using Darcy’s law: 
Eqn. 2-1 𝒖 = −
𝜅
𝜇
𝛻𝑝  
where 𝒖 is the fluid velocity, 𝜅 is the Darcy’s permeability, 𝜇 is the buffer viscosity, and 
𝑝 is the pressure.  Coupling the Navier-Stokes equation with Eqn. 2-1 allowed Darcy’s 
permeability (𝜅) to be iteratively calculated by minimizing the squared error between the 
mean experimental and simulated fluid velocity through the porous media. 
2.3 Results 
2.3.1 Controllable transcollagen scaffold ΔP in a side view thrombosis device 
A microfluidic device was designed with the ability to maintain a computer-
controlled trans-scaffold pressure gradient of ΔP = (P2+P1)/2 – P3, while providing 
constant wall shear stress w (Figure 2-1).  The pressure gradient and wall shear stress 
were controlled by utilizing two independent syringe pumps (Q1, Q2), three pressure 
sensors (P1, P2, P3), and a proportional controller in LabVIEW (Figure 2-2-Figure 2-4) 
to control Q2 based on P1, P2, and P3 at constant Q1.  The syringe pump upstream of the 
scaffold region dictated the wall shear stress while the downstream syringe pump 
controlled the channel pressure for independent control of ΔP and w. 
The scaffold region was designed with six posts equally spaced in a triangular 
orientation (Figure 2-1B and Figure 2-5) to support the loading of fibrous matrix 
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materials such as polymerized collagen.  Pressure ports upstream (P2) and downstream 
(P1) of the scaffold were used for even infusion of a collagen solution during the loading 
protocol by withdrawal from port P3 (Figure 2-5A).  With Q1 and Q2 = 0, the velocity 
profile throughout the posts initially focuses collagen loading in the middle of the 
scaffold where the velocities are roughly twice as fast as the edges (Figure 2-5B).   As 
the middle region is loaded, the edge velocities start to dominate resulting in a uniform 
distribution of collagen at the interface of the main channel (Figure 2-5C).  This 
approach provided a reliable and repeatable method to create a defined protein matrix to 
trigger reactions during the subsequent perfusion of whole blood using Q1. 
After collagen was loaded into the device, the ΔP controller algorithm was 
optimized under diverse conditions.  First, the proportionate control parameter Kp was 
determined to be 0.92 μL/min·Pa using manual tuning to maximize response speed and 
minimize overshoot. The maximum buffer flow rate was set to 100 µl/min to prevent 
overshooting the set point.  Robust control of trans-scaffold ΔP set points was obtained 
under arterial (1130 s-1, 13 µL/min) or venous (174 s-1, 2 µL/min) wall shear rates 
(Figure 2-6A) using whole blood perfusion.  A range of ΔP values from 20.6 to 30 mm 
Hg were achieved at an arterial shear rate.  Similarly, a range of ΔP values from 11.3 to 
22.5 mm Hg were achieved at a venous shear rate. The average response rate was 0.26 
mm Hg/s during set point changes.  Lower wall shear stress required higher buffer flow 
rates to reach larger pressure gradients which caused reduced response rates (0.20 mm 
Hg/s) compared to arterial wall shear stress (0.31 mm Hg/s).  Throughout these 
27 
 
experiments P2 and P1 typically differed by less than 1 mm Hg while P3 remained 
relatively constant. 
For measurement of clot permeability, pulsing of a fluorescent solute tracer under 
constant flow rate was required.  This feature was examined by measuring the trans-
scaffold pressure gradient and buffer flow rate during the injection of a fluorescent dye 
solution at a lower viscosity (µDye=0.001 Pa·s) than that of whole blood (µBlood=0.003 
Pa·s) (Figure 2-6B) [47].  Prior to the introduction of dye (<1 min), the blood viscosity 
in the channel and the Q2 flow rate were constant.  As the dye in buffer solution began to 
exceed the blood concentration (1-3 min, Figure 2-6C), the viscosity of the mixture 
began to drop.  This drop in viscosity was met with an increase in the Q2 flow rate to 
compensate for the reduction in resistance against the Q1 syringe pump.  When the blood 
began to exceed the dye/buffer solution (>3 min), the viscosity began to increase and the 
Q2 flow rate began to decrease to provide a constant resistance against the Q1 syringe 
pump.  Throughout all of these viscosity changes the pressure drop in the channel 
remained constant (23.5 ± 0.12 mm Hg) due to the constant downstream resistance 
maintained by the Q2 flow rate.  The ΔP range that we investigated mimics the range 
located in capillaries.  At the head or heart level lumen pressures are generally 25-30 mm 
Hg [25] and interstitial pressures are within -2-10 mm Hg [26].  While this is the ΔP (15 
mm Hg to 32 mm Hg) we have focused on, higher ΔP values certainly exist in physiology 
and can be achieved in this device. 
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Figure 2-5 Human type I, polymerized collagen localized in the scaffold region. 
Polymerized collagen (2.5 μL) was placed on pressure ports P2 and P1.  A 1 mL syringe 
was used to pull the solution through the scaffold region allowing fibers to wrap around 
the posts.  COMSOL simulations demonstrated the normalized concentration and the 
limited exposure of collagen in the channel during the loading procedure (A). The initial 
velocity field in the scaffold region produces slightly higher velocities in the middle of 
the posts which allowed collagen fibers to load the middle of the region before the outer 
edges (B).  This type of loading resulted in an evenly distributed collagen region with a 
flat collagen-fluid flow interface (C). 
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Figure 2-6 Syringe pump control allows rapid responses to changes in pressure 
set point and fluid viscosity. 
Constant Q1 flow rates provide a constant wall shear rate at the collagen-fluid flow 
interface.  LabVIEW control over Q2, via a downstream syringe pump, allowed pressure 
gradients across the scaffold region to remain constant while responding quickly to set 
point adjustments (A).  In a separate experiment, buffer containing dye was pulsed 
through the device.  As the lower viscosity buffer became more concentrated than the 
blood, the Q2 flow rate increased to maintain pressure at the desired set point (B).  The 
increase in normalized dye fluorescence intensity corresponded to the decrease in 
viscosity and the increase in the downstream flow rate Q2 (C). 
  
30 
 
2.3.2 Transthrombus permeation reduces the intrathrombus zone of thrombin 
activity 
Thrombus development at the collagen or collagen/TF scaffold was followed for 
10 min with a trans-scaffold pressure drop of 23.4 mm Hg.  During the perfusion of 
PPACK anti-coagulated whole blood at an initial wall shear stress of 33.9 dyne/cm2, the 
thrombin deficient clot formed a uniform layer at the collagen/blood interface (Figure 
2-7A-C).  When TF was added to the collagen scaffold and PPACK was replaced with 
CTI, the clot favored larger upstream and downstream platelet deposits rather than the 
uniformity seen in thrombin deficient clots (Figure 2-7D-F).  Using a thrombin sensing 
anti-platelet antibody, we were able to clearly show the thrombin rich layer within the 
clot near the collagen/TF interface during transthrombus permeation.  The clot structure 
was then modeled in COMSOL to analyze the resulting wall shear stress at the surface of 
the clot following 9 minutes of flow.  Due to the shape of the thrombus, the maximum 
shear stress (138 dynes/cm2) was located at the leading edge of the clot and was ~4-fold 
larger than the average clot shear stress (Figure 2-7G). 
Using the platelet-targeted thrombin sensor added to CTI-treated whole blood, the 
thrombin rich region was further analyzed at trans-scaffold ΔP = 0 and 23.4 mm Hg.  The 
thrombin sensor provides a cumulative readout of local thrombin activity. Fluorescent 
line scans from the collagen interface (width=0 microns) and across the clot into the 
blood flow (width=45 microns) were averaged over the entire front-to-back length of the 
clot.  In a diffusion-controlled transport process lacking transthrombus interstitial 
permeation (ΔP=0 mm Hg), the thrombin concentration and boundary thickness were 
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~62% and ~59% larger, respectively, compared to that of clots formed with 
transthrombus permeation (ΔP = 23.4 mm Hg) (Figure 2-8A and Figure 2-8B).  This 
drastic difference demonstrates the importance that transthrombus permeation has on 
soluble agonist localization.  Since an inert protein the size of thrombin (DBrownian ~ 7 x 
10-7 cm2/s) would be expected to diffuse more than 100 microns in 4 minutes, the 
restricted ~15-micron thick region of thrombin activity in Figure 2-8 indicates a 
combination of rapid inhibition by antithrombin, sequestration within fibrin, restricted 
diffusion by platelets, and/or platelet binding (eg. platelet GPIbα).  In addition to the 
thrombin studies, P-selectin positive platelets were also identified.  Figure 2-9 compares 
hierarchical clot architecture using human blood in vitro with previously reported in vivo 
mouse laser injury model [27], demonstrating a remarkable correspondence between 
these two independent approaches, namely the formation of a P-selectin-positive core and 
a surrounding P-selectin-negative shell.  This is the first microfluidic device to recreate 
with human blood the core/shell architecture originally characterized in mouse blood 
vessels.   
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Figure 2-7 Perfusion of anti-coagulated whole blood provides reproducible 
thrombus development at the collagen-blood interface. 
Anti-coagulated whole blood was perfused at an initial wall shear stress (33.9 dyne/cm2) 
while a constant ΔP (23.4 mm Hg) was maintained across the collagen-blood interface.  
Dynamic studies of platelet (red) and thrombin (green) development on collagen (A-C) or 
collagen/TF scaffolds (D-F) allowed for spatial-temporal clot measurements.  Resulting 
structures were simulated in COMSOL to study time-dependent wall shear stress at the 
clot boundary (G). 
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Figure 2-8 Increasing transthrombus pressure gradients caused a reduction in 
thrombin. 
Average line scans of the thrombin boundary layer were taken every two minutes during 
clot formation on a collagen/TF surface.  Whole blood anti-coagulated with CTI was 
perfused for 10 minutes and transthrombus pressure gradients were maintained at ΔP=0 
mm Hg (A) or ΔP=23.4 mm Hg (B).  The increased convection through the clot caused a 
reduction in the presence and velocity of thrombin towards the clot surface. 
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Figure 2-9 Clots formed in the microfluidic injury model we present illustrate 
remarkable correspondence to in vivo hierarchical clot architectures 
found in mouse. 
Fluorescent P-selectin antibodies (green) were used to determine platelet α-granule 
release.   Following 10 minutes of whole blood perfusion (200 s-1) with a ΔP=20 mm Hg, 
a distinct core of P-selectin positive platelets was covered by a shell of P-selectin 
negative platelets (red) in the microfluidic injury assay (A).  The clot architecture of a 
thrombus in a mouse cremaster injury (21, with permission) demonstrates remarkable 
similarities (B).  In both assays only the core or P-selectin positive platelets release their 
α-granules.  This illustrates a level of activation that only the core region of the clot can 
reach during transthrombus permeation. 
  
35 
 
2.3.3 Pressure gradients affect thrombus composition and size 
Using CTI-treated whole blood perfusion, the dynamics of clot composition, wall 
shear stress, and average clot height, in the presence (collagen/TF) or absence (collagen) 
of thrombin, were investigated at transthrombus pressure gradients of 20.8 mm Hg 
(Figure 2-10A-D), 23.4 mm Hg (Figure 2-10E-H), or 0 mm Hg (Figure 2-10I-K).  As 
the clot grew into the flow field, the wall shear stress increased under the constant flow 
rate conditions of the experiment.  Since the average clot thickness (up to 50 µm) was 
small relative to the channel width (250 µm), the wall shear stress only increased 
modestly at constant flow rate.  The calculated clot wall shear stress was averaged in the 
middle 60% of the clot length. 
Comparison of structures formed on collagen versus collagen/TF scaffolds at 
constant transthrombus pressure gradients revealed dramatically different structures.  At 
ΔP = 20.8 mm Hg, the upstream portion of clots on collagen remained larger than the 
trailing edge whereas the trailing edge outgrew the upstream edge when whole blood was 
exposed to collagen/TF surfaces (Figure 2-10A and Figure 2-10B).  In the case of ΔP = 
23.4 mm Hg, the clots developed on collagen were relatively uniform along the length of 
the clot (Figure 2-10E).  At the same pressure, the incorporation of thrombin caused an 
initially larger upstream edge that eventually became uniform with the trailing edge 
following 10 minutes of perfusion (Figure 2-10F).  Noticeably, clots formed without 
transthrombus permeation (Figure 2-10I) looked more similar to clots formed on 
collagen/TF surfaces at ΔP = 20.8 mm Hg, where the trailing edges protruded further into 
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the flow.  This phenomenon has been observed previously in a parallel channel 
microfluidic device at arterial wall shear stress [48].  
Throughout all experiments, clot height decreased when transthrombus pressure 
drop was increased.  Interestingly, only an 11% increase in pressure drop (20.8 mm Hg to 
23.4 mm Hg) resulted in large percent reductions in final clot height for both collagen 
(27.9%, p<0.001) and collagen/TF structures (20.2%, p=0.012) (Figure 2-10C and 
Figure 2-10G).  This trend continued when clots were formed without permeation.  Final 
average clot height at ΔP = 0 mm Hg (TF/Collagen surface) was ~12 μm larger than clots 
exposed to transthrombus pressure gradients of 23.4 mm Hg (Figure 2-10J).  As 
previously discussed in Figure 2-8, the thrombin boundary height was reduced with 
increasing ΔP (Figure 2-10G and Figure 2-10J).  With the increases in clot heights 
came corresponding increases in wall shear stresses from an initial stress of 33.9 
dynes/cm2 to 42.3 dynes/cm2 (platelet structures) or 46.9 dynes/cm2 (platelet/fibrin 
structures) (Figure 2-10D and Figure 2-10H).    
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Figure 2-10 Transthrombus pressure gradients effect dynamic measurements such 
as clot structure, wall shear stress and height. 
Clots formed on collagen (± TF) with transthrombus pressure gradients of 20.8 mm Hg 
(A-D), 23.4 mm Hg (E-H), or 0 mm Hg (I-K) resulted in structural differences based on 
the pressure and the presence or absence of TF.  Thrombus development on collagen 
without TF typically produced smaller clot heights and reduced wall shear stresses.  
Reductions in transthrombus pressure gradients resulted in increased thrombin and 
platelet deposition heights. 
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2.3.4 Fluorescent dye transport allows thrombus permeability measurement 
The designed microfluidic device not only allowed a side view analysis of 
thrombus development under transthrombus pressure gradients, but it was also a versatile 
tool for permeability measurements.  In order to analyze permeability measurements for 
platelet and platelet/fibrin clots formed under flow, the device was validated comparing 
collagen permeability measurements to previous literature values.  Measurements were 
made by injecting a fluorescent dye into the main channel under continuous flow and 
following the progression of the dye at the inlet and outlet of the collagen scaffold.  From 
these curves, an average velocity was calculated by dividing the distance between 
measurements by the time between peak fluorescent intensities on both the inlet and 
outlet measurements.  The calculated average velocities were then matched by 
minimizing the sum squared error between the predicted velocities through the structure 
in COMSOL.  The measured permeability for the collagen scaffold was 1.98x10-11 ± 
0.64x10-11 cm2.  This value was within the range of collagen permeabilities ([41]: 8.9x10-
11 cm2; [42]: 1x10-11 cm2) previously reported.  This measurement was calculated for 
trans-scaffold pressure drops of 11.95 mm Hg, 14.15 mm Hg, and 23.43 mm Hg 
respectively. 
With a validated measurement for the collagen scaffold, the next step was to 
measure the permeability of clots formed with and without thrombin.  The addition of TF 
liposomes to the collagen and substitution of CTI for PPACK allowed us to study 
platelet/fibrin clots.  Measurements were made identical to the techniques previously 
discussed with collagen and the concentration curves were validated by the COMSOL 
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model (Figure 2-11A and Figure 2-11B).  Without thrombin in the system, the platelet 
clot permeability was 5.45x10-14 ± 0.89x10-14 cm2 for ΔP=20.70 mm Hg and 23.53 mm 
Hg (Figure 2-11C).  When thrombin was uninhibited, the time between peak dye 
intensities from the inlet to the outlet increased from 115s to 280s for the representative 
pulse curves.  This increase resulted in a platelet/fibrin permeability of 2.71x10-14 ± 
0.38x10-14 cm2 for ΔP=20.76 mm Hg and 23.34 mm Hg (Figure 2-11C).  The 50% 
reduction in permeability (p=4.6E-4) can be seen by the relative increase in the time 
between peak dye intensities in the representative platelet (Δtplatelet=115s) and 
platelet/fibrin (Δtplatelet/fibrin=280s) clot curves.  COMSOL was utilized to express these 
curves and the normalized dye concentration in the device at t=3.33 min (Figure 2-11D), 
t=5.33 min (Figure 2-11E), and t=7.33 min (Figure 2-11F) for the representative 
platelet/fibrin clot. 
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Figure 2-11 Platelet and platelet/fibrin clot permeability was measured by pulsing 
fluorescent dyes.   
Following platelet deposition, whole blood flow was continuously switched to 
fluorescent dye injection.  Dye fluorescence intensity was measured at the platelet (A) or 
platelet/fibrin (B) interface and collagen exit to predict average fluid velocities across the 
structure.  The permeability of the collagen scaffold, platelet clot, and platelet/fibrin clot 
were calculated using COMSOL to solve for average velocity (C).  Normalized dye 
fluorescence intensity was demonstrated in COMSOL at the time points indicated (D-F).  
The pulse was observed as it permeated through the collagen and platelet/fibrin structure. 
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2.4 Discussion 
The development of in vitro microfluidic assays and in vivo mouse injury models 
have provided many insights into thrombosis and hemostasis under physiologic flow 
conditions [31, 48].  While each assay has advantages, a challenge that remains is the 
ability to study clot development and permeation at higher and lower physiologic 
transthrombus pressure gradients.  In the designed microfluidic device, clot development 
occurs under permeation while being visualized from the side as in the mouse laser injury 
models.  The advantage of incorporating these characteristics into a microfluidic model is 
the ability to control transthrombus pressure gradients and wall shear stress.  This is the 
first reported device that facilitates the independent control of both of these important 
regulators of clot development at physiologic vessel conditions. 
Studies of interstitial flow and its importance in angiogenesis and other cellular 
environments have steadily increased over the last decade.  Incorporating controllable 
pressure gradients and wall shear stress in a model of angiogenesis may provide a more 
realistic in vitro representation of the process as it pertains to human physiology.  In the 
case for thrombosis and hemostasis, minimal changes of transthrombus pressure 
gradients revealed a significant change in clot size and structure.  The increase in 
transthrombus permeation caused by an increase in pressure gradients resulted in 
decreased clot height.  The diffusivity of agonists such as thrombin, ADP, and TXA2 play 
an important role in these observations.  In a thrombin deficient scenario, platelet 
aggregation is primarily achieved by the release of ADP and TXA2 after the initial 
adhesion to the exposed collagen.  The diffusivity of these molecules is much faster than 
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thrombin and as a result, more easily affected by transthrombus permeation [50].  When 
thrombin is present, the reduction in clot size is still noticeable at increased pressure 
gradients but slightly reduced compared to the previous scenario.  This interpretation was 
supported by the reduction in thrombin boundary height in clots formed in the presence 
of transthrombus permeation.  Without pressure gradients, the thrombin was allowed to 
diffuse further towards the surface of the clot.  This suggests that ADP or TXA2 would 
easily reach the clot surface under these conditions but quickly be convected away under 
permeation [51].  Studying the dynamics of thrombosis and hemostasis under 
transthrombus permeation has allowed for a more thorough investigation of the platelets 
response to the physical and biological stimuli present in physiology.  
While clot structure and size were affected by pressure gradients, the permeability 
of platelet and platelet/fibrin thrombus formed under these conditions remained constant.  
Permeability measurements in microfluidic devices are not novel [52], but the 
measurement of thrombus permeability under flow certainly is.  Previous measurements 
have fallen short in their attempt to predict physiologic clot permeability due to the 
omission of clot structure and composition only observed under flow [53].  In this device, 
these critical features were preserved and clot permeability measurements were obtained 
in the presence and absence of thrombin.  The permeability observed in these 
measurements compares closely to previous measurements made in rabbit endothelium 
[54], suggesting that these clots may be a rapidly developing replacement tissue for the 
denuded endothelium.  This would allow the necessary wound healing molecules and 
cells access to the site of injury while maintaining vessel hemostasis.  Incorporation of 
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tissue factor allowed clots to quickly intertwine fibrin into their structure and resulted in a 
significant reduction in permeability as compared to thrombin/fibrin deficient clots.  This 
is important because clots formed in low tissue factors areas such as joints may rely 
solely on thrombin production from the intrinsic pathway [55].  The reduction in their 
permeability allows increased access to the site of injury.  The increase in access may be 
correlated to cases of joint bleeding in hemophiliacs where thrombin production via the 
intrinsic pathway is limited [56].  The device implemented in these studies has proved to 
be a great way to measure permeability and the role of pressure gradients on clot 
development.  Moving forward, this device would provide valuable data to the fields of 
angiogenesis and thrombosis, where interstitial permeation plays a critical role in the 
functionality of the assay. 
2.5 Conclusions 
While investigating thrombus development on a collagen or collagen/TF scaffold 
we were able to conclude that small reductions in transthrombus pressure drop caused 
significant increases in average clot height.  This observation was also observed during a 
study of agonist localization.  In the presence of clot permeation the thrombin boundary 
height and intensity were substantially reduced compared to a scenario where diffusion 
dominated clot transport.  Additionally, measurements for collagen permeability were 
validated with previous literature values and clot permeabilities were easily measured 
under continuous flow conditions at varying pressure drops.  This device provides a novel 
system that is translatable to studies requiring independent control of physiologic trans-
scaffold pressure gradients and/or wall shear stresses.  
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Chapter 3 : Blood clots are rapidly assembled hemodynamic sensors: flow arrest 
triggers intraluminal thrombus contraction 
3.1 Introduction 
During thrombosis or hemostasis under flow conditions, platelets rapidly deposit 
at a site of vascular injury.  The vessel wall and subendothelium quickly become 
connected mechanically to the developing thrombus [57].  During vessel wound closure, 
this interwoven assembly prevents further blood loss by platelet-mediated clot 
contraction and stiffening [58].  Platelets generate contractile forces to allow clots to 
match the stiffness of the endothelium [59].  Interactions between myosin II and actin 
filaments govern this contraction and are regulated by the activation of myosin light 
chain kinase through calcium/calmodulin and/or Rho kinase signaling [60, 61].  During 
contraction, force transmission ultimately occurs via talin and αIIbβ3, which binds 
platelets via fibrinogen and fibrin [62, 63].  Following clot retraction, the tight seal that is 
formed around the injured tissue significantly reduces clot permeability, consequently 
limiting the leakage of cells and plasma.  Also, the permeability of occlusive clots is 
critical to thrombolytic therapy for acute myocardial infarction since permeation dictates 
penetration of plasminogen activators [28].  The effects of local hemodynamics on clot 
contraction and permeability are poorly understood, yet highly relevant to thrombus 
growth, stability, or susceptibility to embolism, fibrinolysis, or bleeding. 
Prior studies of clot permeability have used whole blood clots that do not achieve 
the 50 to 100-fold increase in platelet concentration on a surface that occurs under flow 
conditions [64, 65].  While clot contraction has been studied for decades using clots 
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formed in test tubes, there exists a large gap in the fundamental understanding of 
mechanisms that initiate and control the response under hemodynamic conditions.  In 
terms of force-loading of thrombotic structures, platelets respond with larger stall forces 
when exposed to stiffer fibrinogen-coated atomic force microscopy (AFM) cantilevers 
[59].  Studies of whole clot contraction forces may not necessarily predict clot 
contraction dynamics under flow conditions. 
We measured, for the first time, clot contractility and permeability under 
hemodynamic conditions. The presence of tissue factor caused a significant decrease in 
thrombus permeability.  Unexpectedly, flow arrest caused enhancement of permeability 
for platelet deposits due to a triggered clot contraction and consequent collagen 
restructuring.  To further examine platelet contraction after flow cessation, a rigid wall 
flow device was used.  Platelet deposits were developed and antagonized using 
blebbistatin, a myosin II inhibitor and ADP/thromboxane receptor antagonists.  Flow 
arrest caused an intracellular increase in Ca2+ that preceded contraction and was 
dependent on the autocrine signaling of ADP and TXA2.  These studies provide new 
insight into the ability of platelets to sense local hemodynamic flow based on the 
convective-diffusive transport of autocrine signaling molecules. 
3.2 Materials and Methods 
3.2.1 Reagents 
The following reagents and instrumentation were obtained and stored according to 
manufacturers’ instructions: polydimethylsiloxane (PDMS) (Ellsworth Adhesives); 
sigmacote, streptavidin, sulforhodamine 101 acid chloride (Texas Red), fluorescein 
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isothiocyanate (FITC), and 2-MeSAMP (Sigma-Aldrich); human type-1 monomeric 
collagen (VitroCol, 3 mg/ml) (Advanced Biomatrix);   equine tendon-derived type-1 
fibrillar collagen (Chrono-log); biotinylated goat anti-collagen type I polyclonal antibody 
(Abcam);  0.05 µm Fluoresbrite® microspheres (Polysciences Inc.); fluo4-NW (Life 
Technologies); blebbistatin (EMD Millipore); SQ 29,548 (Cayman Chemical); MRS-
2179 (Tocris Bioscience); anti-fibrin antibody (gift from the M. Poncz, Children’s 
Hospital of Philadelphia); L-α-phosphatidylserine (PS), L-α-phosphatidylcholine (PC), 
and biotinylated phosphatidylethanolamine (bPE) (Avanti Polar Lipids); analog pressure 
transducers (Honeywell Sensing and Control). 
3.2.2 Blood Collection 
All donors were reported as medication free for the previous 10 days and blood 
collection was in accordance with the University of Pennsylvania’s IRB.  Human blood 
from healthy volunteers was collected into 100 µM Phe-Pro-Arg-chloromethylketone 
(PPACK, Haematologic Technologies Inc.) or 40 µg/ml corn trypsin inhibitor (CTI, 
Haematologic Technologies Inc.).  PPACK-treated whole blood was also treated with 
fluorescently conjugated anti-CD41 monoclonal antibody purchased (1 µg/ml; Abd 
Serotec).  PE-conjugated anti-CD61 (0.125 µg/ml; Becton Dickinson Biosciences) and 
fluorescently conjugated anti-fibrin antibodies (0.5 µg/ml) were added to CTI-treated 
blood as previously described [44, 45].    
3.2.3 Permeation device design and manufacture 
PDMS was used to construct microfluidic devices following soft lithography 
protocols [38] as previously described [31, 40, 48].  The primary blood flow channel (250 
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µm wide x 60 µm high) was designed to create flow over a micropost scaffold region as 
illustrated in Figure 3-1A.  At this micropost scaffold junction, blood could continue 
along the primary channel or exit through the scaffold channel (50 µm wide x 60 µm 
high) to an outlet port maintained at P3 = atmospheric pressure or blocked so that P3 
equals the pressure within the blood flow channel.  Real-time pressure measurements 
were collected in LabVIEW (National Instruments) using 0-1 psig pressure transducers 
upstream (P2), downstream (P1) and exiting the scaffold region (P3) as shown in Figure 
3-1.  Channel pressure was controlled using two constant volume syringe pumps 
(Harvard Apparatus).  A syringe pump located upstream of the collagen scaffold 
delivered anti-coagulated whole blood at an independently controlled initial inlet wall 
shear rate (1130 s-1), while a downstream pump perfused Ca2+ buffer (5 mM) at a rate set 
by a proportionate controller programmed in LabVIEW. 
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Figure 3-1  Microfluidic device to independently control blood flow and 
transthrombus pressure drop.   
COMSOL was used to determine the pressure throughout the microfluidic device (A) 
including the collagen scaffold region (B), where L=250 µm.  Human type I polymerized 
collagen was localized in the scaffold region (C).  Following 10 min of CTI-whole blood 
flow at 1130 s-1, platelets (red), fibrin (green) and their overlap (yellow) form a thrombus 
on the collagen (D).  A confocal image of platelets (red) and fibrin (green) shows the 3D 
structure the microfluidic device (E). 
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3.2.4 Microfluidic device for thrombus permeation 
PDMS devices were sealed to Sigmacote-treated glass slides using vacuum-
assisted bonding.  Type I human monomeric collagen solution was polymerized at 2.4 
mg/ml overnight using 8 parts collagen, 1 part 0.09 M NaOH, and 1 part 10x PBS.  Prior 
to loading the scaffold with collagen, all channels were incubated with 10% BSA for 30 
min at room temperature.  Following incubation, well mixed polymerized collagen 
solution was pipette on the upstream and downstream pressure ports and localized into 
the micropost scaffold region by pulling the solution (2.5 µL) through the scaffold exit 
channel with syringe withdraw for ~ 15 s.  A fixed amount of collagen (~ 3.3 ng) was 
thus deposited on the micropost scaffold.  Collagen solution remaining in the channel 
region (between P2 and P1) was removed by infusion of Ca2+ buffer (5 mM) from the 
blood inlet port prior to instillation of blood for the experiment.  For experiments using 
collagen with linked tissue factor (TF), biotinylated and TF liposomes (20:79:1, 
PS/PC/bPE) were prepared as previously described [40, 48] following the method of 
Smith et al. [39].  Polymerized collagen (2.4 mg/ml) was mixed in a 10:1 ratio by volume 
with biotinylated anti-collagen (4 μg/ml) and incubated at room temperature for 5 
minutes.  Streptavidin (10 μg/ml) at a 1:10 volumetric ratio and TF liposomes at a 1:20 
volumetric ratio with collagen were sequentially added and incubated for 5 min and 10 
min, respectively.  The fibrillar collagen/TF solution was then perfused through the 
micropost array region as described for fibrillar collagen. 
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3.2.5 Permeability Measurements 
Whole blood was anti-coagulated with PPACK for perfusion over collagen or 
with CTI for perfusion over collagen/TF.   Each whole blood perfusion was conducted at 
an inlet wall shear rate of 1130 s-1 for 10 min.  The transthrombus pressure drop was 
immediately set to the controlled value and side view images of the platelet or 
platelet/fibrin thrombus were taken at the blood contact region of the collagen scaffold.  
Following thrombus development, an injection valve (Idex Health & Science) was 
manually switched to pulse Ca2+ buffer (5 mM) containing Texas Red or FITC dye (~25 
μL) without disruption of the flow.  Real-time dye, platelet, and fibrin fluorescent 
intensities were imaged with an inverted microscope (IX81, Olympus America Inc.) 
using a CCD camera (ORCA-ER, Hamamatsu).  Confocal images of platelet/fibrin 
thrombus were taken in 2-μm sections, under flow, with a disk-scanning unit (IX2, 
Olympus America).  ImageJ software was used to analyze all images and develop 3-
dimensional representations of thrombus.  
3.2.6 Contraction Measurements 
PPACK-treated whole blood with or without the addition of 50 nm fluorescent 
microspheres (1010 beads/ml blood) was perfused through the permeation device at 1130 
s-1.  Platelet deposits were formed for 10 min under a constant transthrombus pressure 
drop (23.5 mm Hg).  Whole blood flow was then switched without interruption to Ca2+ 
buffer (5 mM) flow.  Following 4.5 min of buffer flow, both syringe pumps were stopped 
and the transthrombus pressure drop immediately approached zero.  Platelet deposits 
were imaged in 15 sec intervals over 30 min. 
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Thrombus contraction studies were also performed in a parallel channel 
microfluidic device [31].  Briefly, a microfluidic device was used to print a 250 μm wide 
strip of diluted fibrillar collagen lengthwise on a Sigmacote treated glass slide.  The 
patterning device was removed and second device was positioned with ten parallel 
channels (250 μm wide x 60 μm high) perpendicular to the collagen.  All channels were 
pre-incubated with 0.5% BSA.  Anti-coagulated whole blood (PPACK) was treated with 
or without an intracellular Ca2+ dye.  Fluo4-NW (2.5 mM probenecid) was loaded into 
platelets by incubating 1 part dye with 4 parts blood for 45 min.  Dye treated or untreated 
blood was then placed in the inlets of three channels.  A syringe pumped allowed 
simultaneous perfusion of the three channels at an initial wall shear rate of 1160 s-1.  
After the collagen patches (250 x 250 μm) were covered with platelets, flow was 
immediately switched to Ca2+ buffer (5 mM, 0.01% DMSO) in the presence or absence of 
antagonist (blebbistatin or mixtures of SQ-29,548, MRS-2179, 2-MeSAMP).  In some 
experiments, buffer flow was stopped (30-sec or 1-min) and then reestablished or 
completely stopped following 7 min of perfusion.  Intracellular Ca2+ fluorescence and 
platelet deposit structures were imaged with a 20x objective, in 15 sec intervals, for the 
duration of the experiment. 
3.2.7 Finite Element Analysis 
COMSOL Multiphysics software was used to numerically solve steady state 
pressure gradients, blood flow velocities and permeation velocities over complex 
geometries (collagen plus thrombus) with constant permeability in the PDMS permeation 
device.  Blood (ρ=1060 kg/m3, µ=0.003 Pa·s) and buffer (ρ=1000 kg/m3, µ=0.001 Pa·s) 
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were both modeled using laminar flow for solution of the Navier-Stokes equation 
(Re=0.49, Reelement=0.25).  The collagen region was modeled using Darcy’s law (∇2P=0) 
with entrance and exit pressures being coupled to the external laminar flow properties 
and permeability (κ) set to a previously determined value (eg. κ = 1 x 10-15 m2) [42].  
Flow rates of 13 μL/min for blood and buffer allowed the downstream resistance length 
to be modified to achieve ΔP=23.5 mm Hg at the collagen scaffold interface.   
Collagen, platelet, and platelet/fibrin permeability were each solved in COMSOL 
for the complex geometries of the collagen scaffold and developed thrombus.  
Calculating and comparing the permeability of collagen to previously reported values 
provided experimental validation of the device [41, 42].  Experimental pressure and 
calculated average velocity data were used as input parameters. The square difference 
between the experimental and computational average velocity across the collagen 
scaffold were iteratively reduced (<0.001 µm2/s2) by varying the collagen permeability.  
With the solved collagen permeability, the process was repeated for the platelet or 
platelet/fibrin geometry on the collagen.  The normalized dye concentration in the 
channel was used as transient input data into the model.  Matching the transient pulse 
concentration at the collagen output with the experimental output validated the 
computational model.  As expected, calculated values of κ were not dependent on ΔP. 
3.2.8 Statistics 
Two-tailed Student’s t-tests were used to calculate all P values.  Statistically 
significant differences were reported if P < 0.05.   
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3.3 Results 
3.3.1 Microfluidic device for measuring clot permeability and contractility 
A microfluidic device was designed to allow pressure-driven transthrombus 
permeation with simultaneous imaging of clot contractile dynamics under flow.  The 
device has a blood and buffer inlet port, collagen scaffold, and three ports for pressure 
readings (P1, P2, P3) up to 50 mm-Hg (Figure 3-1A and Figure 3-2). The downstream 
buffer and upstream whole blood flows merge into a narrow channel to create resistance 
and control the lumen pressure at the collagen site corresponding to (P2+P1)/2.  The 
pressure readings in these locations allowed the pressure drop across the collagen to be 
controlled, thus allowing computer simulation (Figure 3-1B) of Darcy flow through the 
complex geometry assuming constant permeability of the collagen (Figure 3-1C). 
Exposing a 250 µm long x 60 µm wide surface area of collagen (± linked lipidated tissue 
factor) to whole blood flow provided a localized thrombotic site comparable to a previous 
device without permeation [31].  The side view of collagen made it possible to image the 
permeation of dyes and the morphology of fibrin and platelet deposits as they contracted 
(Figure 3-1D and Figure 3-1E).    
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Figure 3-2  A microfluidic device to control transthrombus pressure drop 
independent of shear rate.   
Syringe pump 1 and syringe pump 2 are constant volume pumps that perfuse anti-
coagulated whole blood and 5 mM Ca2+ buffer respectively.  The increased downstream 
resistance due to a narrowed length of channel and the buffer flow causes an increase in 
upstream pressure.  The pressure measurements at P1, P2, and P3 are converted from 
voltages to digital signals which LabVIEW records and uses to proportionately control 
pressure drop via an increase or decrease in syringe pump 2 flow rate. 
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3.3.2 Stopping flow caused platelet and clot retraction 
During permeability testing of platelet deposits (no thrombin), the interruption of 
blood flow resulted in a drastic contractile response of the newly formed clot (Figure 
3-3).  This retraction unexpectedly enhanced permeability due to the reconfiguration of 
the supporting collagen and opening of flow paths along the sides of the collagen (Figure 
3-4).  To investigate the contraction triggered by flow cessation, platelet deposits were 
formed for 10 min with embedded 50 nm fluorescent beads as fiduciary markers (inlet 
wall shear rate of 1130 s-1).  A wall shear rate of 1160 s-1 was used to reproduce rates 
found in capillaries where the pressure drops between the vessel lumen and interstitial 
space are known [25, 26].  This shear rate is also in the range of arterial flows.  Following 
the thrombus formation for 10 min, the flow was switched without interruption to buffer 
for 4.5 min and then flow was completely stopped.  Switching the flow from blood to 
buffer prevented the arrival of new platelets and release of fresh ADP or TXA2 [66, 67].  
Thrombus structure was mapped before and after stopping the flow (Figure 3-3A).  The 
upstream and downstream edge contraction rates were measured throughout the buffer 
flow period and after flow stoppage (Figure 3-3B).  Contraction rates 1 to 2 min after 
flow cessation significantly increased by 6.5-fold (upstream region) and 4.6-fold 
(downstream region) (P<0.05), compared to the rate during buffer flow.  Donor to donor 
variability (n=3 donors) for total clot contraction, 7 minutes after flow arrest, was 8.93 ± 
3.89 μm and 13.6 ± 4.42 µm at the upstream and downstream positions respectively.  The 
restructuring of the thrombus upstream and downstream edges by 2 min post flow 
cessation resulted in contractile trajectories of embedded beads towards the center of the 
thrombus mass (Figure 3-3C and Figure 3-5C).  Comparisons of the time dependent 
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contraction data in the Y and Z direction at upstream and downstream positions of the 
clot demonstrated increased contraction rates after flow cessation (Figure 3-3D).  
Movement in the +Z-direction occurred rapidly and simultaneously in the upstream, 
downstream and middle positions due to an immediate rebound effect caused by a 
reduced pressure drop and reduced permeation when the flow was stopped (Figure 3-5).  
Total bead distance in the Y and Z direction shows the rates at which the clot contracts in 
all three locations (Figure 3-5). The ~1 min delay in contraction in the Y direction is one 
indicator of an active signaling mechanism that must be engaged following the cessation 
in flow. 
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Figure 3-3  Flow arrest triggers clot contraction.   
A thrombus formed in the absence of thrombin and presence of fluorescent 50 nm beads 
was rinsed with Ca2+ buffer for 4.5 min before the cessation of flow caused a rapid 
contraction.  The outline of a pre-retracted thrombus (t’=-1 min) shows the inward 
retraction of the thrombus following flow stoppage (t’=0 to 2 min) (A).  Contraction rate 
of the upstream and downstream sections of the thrombus were measured before and after 
flow arrest (n=3 donors) (B).  Trajectories of the 50 nm beads represent the contractile 
response of the thrombus at upstream (red, n=6), middle (blue, n=3), and downstream 
(green, n=6) locations (C).  Stopping the flow caused a significant increase in contraction 
rate in the Y and Z directions.  To quantify these rates, the times before (0-2 min) and 
after flow cessation (0-1 min, 1-2 min) were monitored for bead velocity in the three 
sections of the thrombus (D).  Downstream contraction rate in Y direction is shown as 
absolute value for contraction toward the middle region.  *, P<0.01; error bars indicate 
mean ± SD. 
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Figure 3-4  Clot permeability. 
Thrombi formed under 1130 s-1 were pulsed with fluorescent dye at controlled pressure 
drops.  The normalized input and output fluorescent intensities, along with a numerically 
predicted output from COMSOL were measured over time for clots formed in the 
absence (A) and presence of TF (B).  Thrombus formed without thrombin reduced the 
residence time of the permeated dye by 30 s compared to platelet/fibrin thrombus.  
COMSOL simulations were used to numerically calculate permeability over collagen 
(n=9), platelet (n=6, 5 donors), platelet/fibrin (n=4, 4 donors), and platelet/flow 
interrupted (n=2, 2 donors) geometries at constant pressure drops (C).  †, P<0.01; error 
bars indicate mean ± SD.  
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Figure 3-5  Spatiotemporal variation of contraction with flow arrest. 
Platelet deposits with 50 nm beads were formed at 1130 s-1 and ΔP=23.5 mm Hg.  
Deposits were rinsed with buffer 4.5 min prior to flow arrest.  Total bead distance was 
measured before and after flow cessation at the upstream, middle and downstream 
positions within the clot, in both the Y (A), and Z directions (B).  The fastest velocity of 
beads travelling in the Y direction was ~1 min following flow arrest.  Conversely, the 
immediate decrease in pressure drop and clot permeation caused the bead distance in the 
Z direction to immediately increase after the cessation of flow.  Bead trajectories were 
mapped in the upstream (red), middle (blue) and downstream (green) portions of the clot 
throughout the duration of the experiment (C). 
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3.3.3 Permeability of collagen, platelet deposits, and platelet-fibrin thrombus 
without flow interruption 
To measure permeability without triggered thrombus contraction, dye tracer was 
pulsed immediately following whole blood flow without interruption of the flow.  Inlet 
and outlet concentrations were measured with time to determine the permeation velocity 
at several physiologic pressure drops [25, 26].  Permeability was numerically calculated 
over the complex geometry (Figure 3-4A and Figure 3-4B) by reducing the squared 
error between the experimental and simulation permeation velocity.  We validated this 
approach by comparing our calculated collagen permeability (κcollagen = 1.98x10
-11 ± 
0.640x10-11 cm2) with previous literature values (Figure 3-4C) [41, 42].  Similarly, 
permeation velocity was measured across platelet deposits and platelet-fibrin thrombi 
formed on collagen or TF/collagen scaffolds, respectively.  Simulations that accurately 
predicted the experimentally measured output of dye concentration over the course of 
these experiments allowed determination of the permeability of the thrombus (Figure 
3-4A and Figure 3-4B). The resulting permeabilities for platelet deposits (κplatelet = 
5.45x10-14 ± 0.898x10-14 cm2) and platelet-fibrin thrombus (κthrombus = 2.71x10
-14 ± 
0.377x10-14 cm2) formed after 10 min of flow quantify the resistance that each structure 
provides to resist bleeding.  In the absence of thrombin, PPACK-treated whole blood 
formed a platelet mass that was >350-fold less permeable than collagen alone.  The 
presence of thrombin and formation of fibrin provided a further 50% reduction in 
permeability under hemodynamic conditions.  Comparing the measured platelet deposit 
permeability (without flow interruption) to that obtained following flow interruption 
(κinterrupted = 2.91x10
-13 ± 0.745x10-13 cm2) demonstrated the impact that stopping the flow 
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had on the ability of the platelet deposit to maintain hemostasis in our device.  In addition 
to permeability measurements, we observed decreased platelet accumulation with 
increased pressure drop (13.8 vs. 23.4 mm Hg) across the intraluminal thrombus in 
PPACK-treated whole blood (Figure 3-6), likely due to increased transthrombus 
permeation of ADP and TXA2 into the collagen. 
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Figure 3-6  Transthrombus pressure drop affects platelet deposition. 
PPACK-treated whole blood was perfused over a permeable scaffold of collagen at 1130 
s-1 for 10 min.  Platelet fluorescence intensity was measured for the platelet deposits 
formed at a low (ΔP=13.8 mm Hg, n=3) and high (ΔP=23.4 mm Hg, n=3) pressure drops.  
Increased transthrombus pressure drops caused a significant decrease in platelet 
deposition at the site of injury.  Data was collected using 5 separate donors; error bars 
indicate mean ± SD. 
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3.3.4 Clot retraction in a rigid wall flow device with flow reduction or cessation 
Clot retraction was also examined in a rigid, impermeable parallel-plate 
microfluidic device lacking transthrombus permeation.  Clot development in PPACK-
treated whole blood was imaged on a 250 µm x 250 µm area of glass-supported fibrillar 
collagen at an initial wall shear rate of 1160 s-1.  Flow cessation resulted in a ~10 µm 
contraction (upstream region) towards the center of the thrombus as outlined in Figure 
3-7A.  In comparison, by switching to 10 µM blebbistatin perfusion (without flow 
disruption) for 7 min before the flow cessation, clot retraction after flow cessation was 
reduced 90% to only ~1 µm (Figure 3-7B).  Blebbistatin is a well established platelet 
myosin IIA ATPase inhibitor [68].  In a scenario where flow was reduced from arterial 
(2000 s-1) to venous (100 s-1) shear rates, total contraction was similar to that observed 
with flow cessation.  Also, the contraction was ~5 µm larger than stopping the flow 
following blebbistatin treatment (Figure 3-8).  This result demonstrates the requirement 
of platelet myosin IIA activity in the triggered thrombus contraction following flow 
reduction or cessation.  
We also measured clot retraction while stopping and restarting flow after a 30-sec 
or 1-min interruption (Figure 3-7C).  Statistical differences between complete cessation 
of blood or buffer and the 30-sec flow interruption became apparent after 1 min.  
Interrupting flow for 1 min took 5 min to diverge statistically from complete flow 
cessation in buffer.  While neither of the temporary flow interruptions (30-sec or 1-min) 
were statistically different from each other, the longer 1-min delay provided enough time 
to engage the contraction mechanism before eventually being diminished by the return of 
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flow.  The technique of switching to a non-physiologic buffer and measuring contraction 
was validated by showing no contractile differences between stopping the flow in blood 
or stopping buffer flow after 7 min of rinsing.  
Since flow cessation results in a dramatic change in both wall shear stress and 
wall shear rate on the thrombus structure, we investigated the role of soluble autocrine 
mediators whose concentration may change when flow is stopped.  To explore the role of 
TXA2, we added 1 µM SQ-29,548, a potent TXA2 receptor antagonist [69].  Additionally, 
the contribution of ADP was investigated by adding 10 µM MRS-2179 and 50 µM 2-
MeSAMP, selective inhibitors of the P2Y1 and P2Y12 platelet receptors, respectively 
[70].  The dose response curves for these inhibitors have been well established and the 
final concentrations used under flow exceeded the experimentally determined IC50 
values to ensure complete inhibition [69, 70].  After 7 min of buffer/antagonist perfusion, 
flow was stopped and total contraction was measured with time (Figure 3-7D).  Both 
antagonists significantly reduced the total clot contraction as compared to buffer.  ADP 
antagonists had the largest effect, reducing the total contraction nearly 75% over 7 min, 
whereas TXA2 antagonist reduced the contraction by 44%.  While uninhibited contraction 
can vary significantly between donors (~32-44%), the addition of antagonist results in 
consistent donor to donor percent reductions that vary <7% for ADP and <3% for TXA2.  
These findings demonstrate ADP (from dense granules) and TXA2 from activated 
cyclooxygenase-1 (COX1) were the mediators of the triggered contraction response upon 
flow cessation.  
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Figure 3-7  Contraction after flow arrest requires myosin and released 
ADP/TXA2. 
A parallel channel microfluidic device was used to develop thrombus in PPACK, at 1160 
s-1.  Following the formation of stable thrombi, Ca2+ or antagonist buffer was used to 
rinse the surface for 7 min before stopping flow.  Upstream contractions were observed in 
five sections (blue dashed line) over ten min.  Stopping flow without a buffer rinse (A) 
and with a 10 µM blebbistatin rinse (B) show clot retraction compared to a trace (pink 
line) before flow cessation.  Total clot contraction measured over time compares the 
effects of blebbistatin and intermediate flow stopping with stopping flow with and 
without a buffer rinse (C).  TXA2 and ADP antagonist significantly reduced total 
contraction after flow cessation as compared to buffer (D). n=3 events at 5 discrete points 
for each time-point indicated, using 5 separate donors; error bars indicate mean ± SD. 
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Figure 3-8  Platelet flow sensing occurs when arterial flow is reduced to venous 
flow.  
A parallel channel microfluidic device was used to perfuse PPACK whole blood with 
labeled platelets over patterned collagen at an initial wall shear rate of 2000 s-1.  Arterial 
shear rates were reduced to 100 s-1 (venous) following the deposition of labeled platelets 
at the site of injury.  Total contraction of the platelet deposits for three donors (n=7 total 
events) were followed immediately after the reduction in shear rate.  Significant 
contraction was observed and can be compared to stopping flow following blebbistatin 
treatment (n=3).  Error bars represent mean ± SD. 
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3.3.5 Intracellular calcium mobilization is triggered by ADP and TXA2 after flow 
cessation 
To explore the role of ADP and TXA2 in the flow sensing by the thrombus, we 
loaded platelets in PPACK-treated whole blood with Ca2+ sensitive dye fluo-4.  Prior to 
flow cessation, we treated the platelet deposits with buffer in the presence and absence of 
a triple cocktail of 1 µM SQ-29,548, 10 µM MRS-2179, and 50 µM 2-MeSAMP.  To 
minimize the measured intracellular Ca2+ fluctuations prior to flow cessation, initial 
contraction measurements were made 3 min after treatment and 3 min before flow arrest.  
The calcium signal increased as the platelet mass accumulated on the collagen between 0 
and 4 min.  When flow was switched to buffer at 4 min, there was no further deposition 
of platelets resulting in a slight decrease in signal.  In the absence of inhibitors, flow 
cessation at 10 min caused an immediate and substantial mobilization of intracellular 
calcium (Figure 3-9A) that was completely blocked by the triple inhibitor cocktail to 
antagonize ADP and TXA2 (Figure 3-9B).  The calcium mobilization occurred within 
seconds following flow cessation and preceded the maximum platelet contraction rate 
which began 1 to 2 min after flow stoppage (Figure 3-10). 
The triggered contraction by the platelet mass, following flow cessation, is an 
active material response requiring myosin (Figure 3-7C) and represents a flow sensing 
mechanism to impede contraction when flow is present.  ADP and TXA2 are the soluble 
mediators responsible for this response (Figure 3-7D and Figure 3-9B).  Both of these 
agonists are highly sensitive to convective dilution which controls their concentrations in 
the boundary layer around the thrombus [51].  Since soluble species mediated Ca2+ 
mobilization and contraction upon flow cessation, the flow sensing involved a transport 
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mechanism: flow dilutes soluble species and flow cessation allows a rapid accumulation 
of autocrinic ADP and TXA2 to trigger Gq signaling via platelet P2Y1, P2Y12, and TP 
receptors (Figure 3-9C). 
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Figure 3-9  Flow cessation triggers platelet intracellular calcium mobilization via 
ADP/TXA2 autocrine signaling.   
Platelets in PPACK whole blood were loaded with Ca2+ dye and perfused over collagen 
at 1160 s-1.  Following thrombus formation, whole blood perfusion was switched to Ca2+ 
or antagonist buffer for six minutes prior to stopping flow.  Intracellular Ca2+ was 
measured via fluorescent intensity over time for either a Ca2+ buffer (A) or ADP and 
TXA2 antagonist rinse (B).  n=3 events using 2 donors, error bars indicate mean ± SD.  A 
schematic illustrates the flow sensing ability of platelets via convective removal of 
ADP/TXA2 (C).  Shear () acting on the exterior of aggregated platelets accompanied by 
the strain placed on interconnected αIIbβ3 may signal the inhibition of contraction or dense 
granule (δ) release. 
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Figure 3-10  Treating platelet deposits with ADP and TXA2 antagonist caused a 
significant decrease in contraction rate following the cessation of flow.   
Platelet deposits were formed on patterned fibrillar collagen in rigid wall, parallel 
channel flow devices at 1160 s-1.  Following platelet clot development, PPACK blood 
flow was continuously switched to buffer (5 mM Ca2+, n=3), 10 µM MRS-2179 and 50 
µM 2-MeSAMP (ADP antagonist, n=3), or 1 µM SQ-29,548 (TXA2 antagonist, n=3) for 
7 min.  Flow was stopped and contraction rates were measured before and after.  Data 
was collected using 1 donor and each independent event was analyzed at 5 discrete 
points; error bars indicate mean ± SD. 
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3.4 Discussion 
We report a novel hemodynamic sensing function of intraluminal blood clots.  
Flow impedes clot retraction.  When flow stops, intraluminal clots retract more rapidly 
and to a greater extent.  This hemodynamic sensing by platelets in thrombus involves a 
rapid mobilization of calcium that strictly requires released ADP and TXA2.  Myosin 
activity is also required for the triggered contraction upon flow cessation, indicating that 
the contraction is not a passive material response to reduced drag forces.  This concept of 
a triggered, active response is also consistent with the ~1 min delay between flow 
cessation and enhanced contraction. 
While platelet contraction of a clot is usually considered in an isotropic context 
where blood is clotted in a tube and then detached from the glass walls to allow 
contraction, intraluminal thrombus formation is fundamentally different.  In an isotropic 
assay, platelets have random orientation within a fibrin network whereas platelets 
depositing under flow conditions spread on collagen and then form many more platelet-
platelet interactions due to high platelet concentration in the thrombus.  In the thrombus 
formed under flow, the structure is less isotropic and spread platelets would be expected 
to exert greater forces along their axis of spreading and lesser forces perpendicular to the 
plane of spreading.  Furthermore, clotted whole blood in a tube contains incompressible 
red blood cells at the prevailing hematocrit, while thrombus formed under arterial flow 
are greatly enriched in platelets (50-100X platelet rich plasma levels) and substantially 
depleted of RBC. 
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Despite recent advances in microfluidic devices and intravital mouse microscopy, 
few tools are available to control and study the effects of thrombus permeation under 
flow conditions.  Recent studies examining angiogenesis demonstrated microfluidic 
devices that hold promise for studying in vitro clot permeability under flow conditions 
[36, 41].  However, these designs lacked the potential to produce controllable pressure 
drops and shear rates relevant to thrombosis and hemostasis.  In the present study, we 
designed a microfluidic device to develop whole blood clots under physiologic flow and 
to investigate transthrombus permeation in the presence of a controlled pressure drop.  
The microfluidic device allowed the first reported in vitro clot permeability for clots 
formed under flow.  While a measurement for the permeability of a contracted clot could 
not be obtained due to the accompanied structural changes in the absence of endothelium, 
it is expected to be less than that of a non-retracted platelet-fibrin deposit.  Our 
measurement for these deposits represents a quantitatively important upper bound of the 
contracted clot permeability and the associated inner clot transport of ADP and TXA2.  
Interestingly, the permeability of healthy rabbit aortic wall is on the order of 10-14 cm2 
[54], which is quite similar to our measurement of a platelet-fibrin thrombus.  This 
suggests that a platelet-rich intraluminal thrombus has a permeability that is well matched 
to the surrounding intact endothelium.  In addition to matching rigidity [59], an 
intraluminal thrombus may match permeability to the surrounding vessel wall.  Under 
flow conditions, we propose flow sensing helps the spread platelet(s) maintain hemostatic 
function by balancing the contractile apparatus with the applied flow to limit platelet 
contraction since contraction would potentially create gaps for leakage or alter nearby 
endothelial function. 
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In a quantitatively more intense example of hemostasis, a blunt impact that 
compresses a vessel without rupturing the vessel would be expected to cause more 
extensive endothelial denudation.  This situation is perhaps most analogous to the 
experimental configuration developed in this study.  When blood flow is maintained in 
such an injured vessel, the flow impedes clot contraction because wound closure would 
not be needed.  Also occlusion might be prevented since clot stabilization via contraction 
is impeded by flow.  Reduced ADP/TXA2 transport may also facilitate the formation of a 
dense inner thrombus core [71], while the outer domains of the clot remain loose and 
friable due to flow sensing.  Throughout our studies with multiple donors, this was 
repeatedly verified by the constant but relatively low contraction rate under flow (Figure 
3-3B and Figure 3-11).  As vessel injury becomes severe enough to cause vessel rupture 
with blood leaving the vascular space, blood pools around the puncture/rupture/severed 
site.  This results in more isotropic clotting of whole blood, which can exert isotropic 
contraction on the surrounding tissue to facilitate wound closure and consequently 
hemostasis (Figure 3-12).  In this situation, the pooled blood around a leaking vessel is 
not subjected to substantial hemodynamic flow to dilute ADP/TXA2 and thus impair 
platelet actinomyosin-mediated contraction.  Additional highly diffusible platelet 
activators may also play a role in this observed contraction and provide an area of future 
study. 
To further investigate the novel flow sensing abilities of platelets we examined 
their ability to contract following 30 seconds or 1 minute interruptions in flow.  
Contraction rates initially followed previous experiments but were drastically dampened 
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upon the return of flow (Figure 3-13).  This result suggests that the quasi-steady state 
that platelet deposits reach under hemodynamic forces preserves their ability to rapidly 
contract in response to flow arrest.  Flow sensing by a thrombus balances the need for 
wound closure and hemostasis against the risk of intraluminal occlusive thrombosis with 
dense contracted and lytic-resistant structures [72].  In cases of normal hemostasis, this 
mechanism would allow clots to contract gradually from their interior towards their 
exterior as hemodynamic flow is reduced.  The extent to which stress present in the 
thrombus plays a role in signaling (i.e. mechanotransduction) remains a subject of future 
study.  These experiments clearly demonstrate the ability of platelet deposits to rapidly 
assemble into a hemodynamic sensor and contract upon the arrest of flow. 
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Figure 3-11  Blebbistatin, a myosin IIA inhibitor, reduced contraction rates before 
and after flow cessation.   
Whole blood anti-coagulated with PPACK was perfused at 1160 s-1 over impermeable 
collagen in a parallel channel flow device.  Flow was stopped immediately (blood, n=3) 
or following a 7 min rinse with 5 mM Ca2+ buffer (n=3) or 10 µM blebbistatin (n=3).  
Rinsing platelet deposits with buffer for 7 min was not significantly different than a 
physiological flow arrest in blood.  Data was collected using 2 separate donors and each 
independent event was analyzed at 5 discrete points; error bars indicate mean ± SD.  
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Figure 3-12  Platelet contraction is dependent on local hemodynamic flow 
conditions. 
For blood clotted under static conditions platelets can exert isotropic contraction (A).  
When platelets spread on a surface, contraction becomes anisotropic due to platelet 
morphology (B).  When non-occlusive intraluminal thrombi form at sites of plaque 
rupture (C) or denuded endothelium (D), contraction is limited due to the thrombus flow 
sensing where autocrine agents are controlled by convective transport.  However, 
punctured (E) or severed (F) vessels, where flow is substantially decelerated, allows 
isotropic contraction of platelets and surrounding tissue to securely close the wound. 
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Figure 3-13  Reestablished flow dampens contraction mediated by temporary flow 
interruption. 
Parallel flow channels were used to form platelet deposits in PPACK whole blood at 
1160 s-1.  Following the development of the deposits, flow was continuously switched to 
buffer for 7 min.  Immediately following the rinse, flow was interrupted and resumed 
after 30-sec (n=3) or 1-min (n=3).  There were no significant differences in the 
contraction rates between the two interruption times due to the reestablished 
hemodynamic flow conditions.  Data was collected using 1 donor and each independent 
event was analyzed at 5 discrete points; error bars indicate mean ± SD. 
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Chapter 4 : Fibrin, ’-fibrinogen, and trans-clot pressure gradient control 
hemostatic clot growth during human blood flow over a collagen/tissue factor 
wound  
4.1 Introduction 
During hemostasis, stable clot formation at the site of wounding is facilitated by 
the growth of a platelet plug and the generation of fibrin. Essential to vascular integrity, 
this structure must form rapidly under flow at an injury site, withstand hemodynamic 
forces, and prevent pressure-driven blood loss. With the laser injury mouse model, the in 
vivo architecture of the hemostatic clot has been revealed to contain two distinct regions 
of platelet activation: an inner tightly packed ‘core’ with extensive α-granule release and 
an unstable outer ‘shell’ with minimal α-granule release [27].  α-granule release is 
identified by P-selectin display and is characteristic of the core.  Recent mouse studies 
have shown that the core region is thrombin and fibrin rich, platelet-retracted with lower 
porosity and reduced albumin mobility, and localized to the interior of the clot closest to 
the injury site. In contrast, the shell region is thrombin and fibrin poor, more porous and 
localized to the exterior of the clot towards the vessel lumen, and displays significant 
platelet turnover [27, 73-75]. 
The regional heterogeneity of platelet activation in clots highlights the 
complexities of when and where agonists are localized and what biochemical and 
physical parameters regulate hemostatic clot development. Importantly, the factors that 
trigger wall-attached clots to become fully occlusive thrombi are not fully understood, 
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but may include platelet hyper-reactivity, dysregulated thrombin production, and 
enhanced vWF function in pathological stenotic flows [76-78]. 
Thrombin is a potent platelet activator at ~1 nM and cleaves fibrinogen to drive 
fibrin polymerization at ~10 nM or higher.  In humans, the -chain of fibrinogen has two 
expression variants: A (main form) and ’ (splice variant).  The ’-chain contains a 20-
amino acid extension due to alternative mRNA splicing [79].  Unique to ’-fibrinogen is a 
high affinity binding site for exosite II on thrombin [80].  While A/’ fibrinogen only 
makes up about 8-15% of total fibrinogen, ’-fibrinogen can serve as a sink for locally 
produced thrombin [81-83]. Also, Factor XIII has a 20-fold higher affinity for the A/’ 
fibrinogen heterodimer than the A/A fibrinogen homodimer [84]. 
Using microfluidics and human blood, our prior studies have demonstrated that 
fibrin polymerization stabilizes clots by anchoring the clot to the injury site with ~12 to 
28-fold greater resistance to shear forces [48].  Our goal was to study the impact of 
fibrin(ogen)’s antithrombin properties and fibrin polymerization on thrombin mediated 
clot growth in human blood.  Mouse models do not allow precise control of: prevailing 
shear rates, trans-thrombus pressure drops, or biochemical constituents of the wound.  
Additionally, mice lack the ’ splice variant of fibrinogen [85].  In order to study 
fibrin(ogen)’s role in the hemostatic growth of thrombi, it was critical to have 
reproducible hemodynamics. There are few studies that demonstrate the ability to 
simultaneously measure and control wall shear rate and trans-clot pressure gradients 
(ΔP).  This limitation motivated our previous work on designing a microfluidic device 
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capable of independently controlling both wall shear rate and ΔP [46, 86].  Using this 
device we have now studied the localization of thrombin, the role of thrombin in platelet 
P-selectin display, and the role of fibrin polymerization and ’-fibrinogen in regulating 
fibrin function.  We report that fibrin, in addition to stabilizing clot structures against 
shear forces [48], is critical in localizing and restricting thrombin to the core region of a 
hemostatic clot. 
4.2 Materials and Methods 
4.2.1 Materials 
The following instrumentation and reagents were used:  analog pressure 
transducers (Honeywell Sensing and Control); human type-1 monomeric collagen 
(VitroCol, 3 mg/ml) (Advanced Biomatrix); recombinant tissue factor (Dade® Innovin®; 
Siemens); Sigmacote® (Sigma-Aldrich); polydimethylsiloxane (PDMS) (Ellsworth 
Adhesives); anti-fibrin antibody (gift from M. Poncz, Children’s Hospital of 
Philadelphia); anti-fibrinogen ’ antibody (clone 2.G2.H9) and H-Gly-Pro-Arg-Pro-OH 
(GPRP, EMD Millipore); peak 1 fibrinogen (XIII free) and peak 2 fibrinogen (Enzyme 
Research Laboratories); anti-human CD62P antibody (BD Biosciences); anti-human 
CD41 antibody (AbD Serotec); anti-human CD32 antibody (STEMCELL Technologies 
Inc.); Boc-VPR-AMC fluorogenic peptide substrate (R&D Systems®). 
4.2.2 Blood Collection 
All blood donations were conducted in accordance with the IRB at the University 
of Pennsylvania.  Human blood was drawn via venipuncture from healthy volunteers 
reported as both alcohol and medication free.  Studies conducted in the presence of 
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thrombin were completed with blood drawn directly into 40 µg/ml corn trypsin inhibitor 
(CTI, Haematologic Technologies Inc.).  Thrombin free investigations were performed 
with blood anticoagulated with 40 µg/ml CTI, 100 µM Phe-Pro-Arg-chloromethylketone 
(PPACK, Haematologic Technologies Inc.), and 1 µM Apixaban (Selleck Chemicals, 
Houston, TX, USA).  Platelets were labelled with a fluorescently conjugated anti-CD41 
monoclonal antibody (1 μg/ml, Abd Serotec) and P-selectin was labelled with a PE-
conjugated anti-CD62P antibody (0.0625 μg/ml, Becton Dickinson Biosciences).  
Thrombin localization was visualized using either 5 µM Boc-VPR AMC or a thrombin 
sensitive antibody (5 µg/ml, ThS-Ab) [43].  Fibrin studies were performed with 0.5 µg/ml 
of a fluorescently conjugated, fibrin specific antibody (gift from the M. Poncz lab, 
Children’s Hospital of Philadelphia) [44, 45]. 
4.2.3 Microfluidic device for control of wall shear rate and trans-clot ΔP 
The microfluidic device fabrication has previously been described [38].  In brief, 
negative photoresist (KMPR 1050, MicroChem Corp.) was patterned on silicon wafers 
(D=100 mm, WRS Materials) using photolithography techniques.  Soft lithography was 
then used to fabricate polydimethylsiloxane (PDMS) devices from the patterned wafers.  
The devices were designed with two inlets, two outlets, a post scaffold region and three 
pressure ports.  Holes for tubing (0.020” ID x 0.060” OD, Cole-Parmer) and blunt 
needles (Small Parts) were punched with 0.75 and 0.5 mm I.D. corers (Harris Uni-
CoreTM, Ted Pella, Inc.)  The main channel was comprised of two pressure ports, one 
upstream and one downstream of the post scaffold region.  These pressure ports were 
used to load the post scaffold region with polymerized type I collagen ± tissue factor (TF) 
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following treatment with 10% bovine serum albumin (BSA).  Scaffold loading was 
accomplished by pulling the collagen solution through the main channel pressure ports 
out through the scaffold outlet.  The entire channel was immediately rinsed following 
scaffold loading to remove any remaining fibers outside of the scaffold.  After the 
channels were rinsed and loaded, the three pressure ports (main channel upstream, main 
channel downstream, and scaffold exit) were hooked up to pressure transducers 
(Honeywell Sensing and Control).  The main channel inlet was connected to a whole 
blood syringe that was perfused by a constant volume syringe pump (PHD Ultra, Harvard 
Apparatus).  The downstream inlet was connected to a buffer syringe that was perfused 
by a controlled constant volume syringe pump (PHD 2000, Harvard Apparatus).  The 
buffer pump was controlled via a PID controller designed in LabVIEW (National 
Instruments).  Briefly, the controller maintains constant channel pressure by reading 
channel pressure measurements (NI USB-6210, National Instruments) and adjusting the 
buffer pump flow rate.  PID settings were calculated using the Ziegler-Nichols tuning 
method.  These settings facilitated simultaneous control over multiple channels (Figure 
4-1). 
Devices were set up on an inverted microscope (IX81, Olympus America Inc.) 
with a three slide holder.  Anticoagulated whole blood perfused through the channel at a 
constant wall shear rate was labelled with fluorescent antibodies for imaging using a 
CCD camera (ORCA-ER, Hamamatsu).  Clots were imaged from a side view prospective 
as they developed on the localized collagen ± TF scaffold.  Unique to this design is the 
ability to independently control both the inlet flow rate (wall shear rate) and the 
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transthrombus pressure gradient (ΔP) as the clots developed.  Wall shear rates ranged 
from a venous shear rate of 100 s-1 to an arterial shear rate of 2000 s-1 [23].  All 
transthrombus pressure gradients were maintained within a physiologically relevant range 
(ΔP=9-30 mm Hg) [25, 26]. 
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Figure 4-1 Independent pressure control was achieved in three channels 
simultaneously. 
Dynamic pressure measurements were made using 0-1 psig pressure sensors at a constant 
wall shear rate.  All three channel pressures were controlled within 2.5% tolerance (A).  
PID control was used based off of the average of all channels and was maintained within 
a 1% tolerance of the set point (B). 
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4.2.4 Fibrin polymerization and ’ fibrin(ogen) inhibition 
Studies investigating fibrin polymerization were completed with GPRP.  Whole 
blood anticoagulated with CTI or CTI/PPACK/Apixaban was incubated with HEPES (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid)-buffered saline (HBS) or 5 mM GPRP 
for 5 min.  Two channels were then perfused simultaneously with the control (HBS) and 
5 mM GPRP whole blood samples.  Both channels maintained a constant wall shear rate 
(100 s-1, 400 s-1, or 2000 s-1) and ΔP (20 mm Hg). 
An anti-human CD32 antibody and an anti-fibrinogen ’ antibody were both used 
to investigate ’ fibrin(ogen)’s role in thrombin regulation. CTI whole blood was labelled 
with platelet, P-selectin, thrombin, and FcγRII antibodies for 5 min.  Antibodies specific 
for FcγRII were used to prevent CD32-mediated platelet activation following incubation 
with anti-fibrinogen ’ antibodies.  Fibrinogen ’ antibody free control buffer (0.1M Tris-
glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide, 30% glycerol) was added to one 
sample and anti-fibrinogen ’ antibody was added at a 1:1 molar ratio with ’ fibrin(ogen) 
(0.3 mg/ml) [87].  Following 5 min, four channels were perfused simultaneously at a 
constant ΔP (16 mm Hg).  Two channels were perfused at 100 s-1 and the other two were 
perfused at 2000 s-1, both shear rates had one buffer control sample and one ’ 
fibrin(ogen) antibody sample. 
4.2.5 Mouse cremaster arteriole laser injury model 
Male mice 8-12 weeks of age were anesthetized with an intraperitoneal injection 
of sodium pentobarbital (90 mg/kg), and their jugular vein was cannulated for the 
introduction of fluorescent biomarkers. The mouse cremaster was exposed, cleaned of 
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connective tissue, opened, and prepared for viewing by intravital microscopy.  The 
cremaster was maintained under a constant flow of bicarbonate buffer (37 C) bubbled 
with 95%/5% N2/CO2.  Mouse arterioles of 30-50 μm diameter were visualized with a 
BX61WI microscope (Olympus, St. Louis, MO, USA) with a 60X (0.9 NA) water 
immersion objective, and a CSU-X1 spinning disk confocal scanner (Yokogawa, Sugar 
Land, TX, USA).  Fluorescence imaging was done using diode pumped solid state lasers 
(405 nm, 488 nm, 561 nm, 647 nm) with AOTF control as an excitation source 
(LaserStack, Intelligent Imaging Innovations, Denver, CO, USA), and images were 
captured using an Evolve digital camera (Photometrics, Tucson, AZ, USA).  Endothelial 
cell ablation was performed with a pulsed nitrogen dye laser (SRS NL100, 440 nm) 
focused on the vessel wall through the microscope objective.  The laser was fired 
between 1-10 times until red blood cells either escaped into the extravascular space or 
became trapped within the layers of the vessel wall.  The University of Pennsylvania 
Institutional Animal Care and Use Committee approved all procedures. Platelets and P-
selectin were labeled with fluorescent anti-
Germany, Clone: Xia.C3) and anti-CD62P respectively. Thrombin activity was measured 
using the previously described mouse thrombin sensor antibody (mThS-Ab). These 
fluorescent markers were imaged once per second for 3 minutes.  Background 
fluorescence was measured within the vessel and subtracted from the images to determine 
staining intensities. 
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4.2.6 Image processing 
Raw image stacks were processed by ImageJ (NIH).  All stacks were background 
corrected using the “Subtract Background” feature in ImageJ.  This feature averages the 
background over domains using a rolling ball approach [88].  Following background 
correction, images were thresholded using the triangle method [89, 90].  Binary images 
were then cropped to the middle 68% (first post to last post) of the clots while retaining 
the entire clot width.  Total area was calculated for each frame and fluorescent tag.  
4.2.7 Statistics 
P values were calculated using paired or unpaired, two-tailed student’s t-tests. 
Statistically significance was reported if P<0.05. 
4.3 Results 
4.3.1 Microfluidic device for investigating clot architecture at controlled wall shear 
rates and transthrombus pressure gradients 
Thrombi were developed in vitro using a microfluidic device (Figure 4-2A).  Clot 
formation was initiated when CTI whole blood was perfused across a post scaffold region 
loaded with collagen/TF (Figure 4-2B). The architecture of the developing clot was 
investigated from a side-view perspective at independently controlled wall shear rates 
and trans-clot pressure gradients.  Clots formed within this microfluidic device, on 
collagen/TF scaffolds demonstrated distinct P-selectin positive and negative areas 
(Figure 4-2C).  The P-selectin positive region (core) remained localized to the interior of 
the clot, closest to the collagen/TF surface.  The P-selectin negative region (shell) 
enclosed the interior core region and remained exposed to the flowing whole blood.  We 
have previously reported the ability of our device to generate these core/shell 
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architectures, which have only been observed in vivo [27, 86].  Recently, thrombin was 
revealed as the primary agonist responsible for core development in vivo during mouse 
arteriole laser injury [27, 73-75]. These results align with investigations we made using 
the soluble thrombin activity peptide, Boc-VPR-AMC where the highest thrombin 
activity was localized to the core region (Figure 4-2D).  This is the first report of 
thrombin localization to the core region of human blood clots. 
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Figure 4-2 Thrombus architecture was investigated in a microfluidic device 
capable of independently controlling transthrombus pressure 
gradients and wall shear rates. 
Anticoagulated whole blood was perfused at a constant wall shear rate (Q1) while the 
transthrombus pressure gradients (ΔP) were independently controlled via downstream 
buffer infusion Q2 (A).  Polymerized collagen ± TF was localized to a post scaffold 
centered between pressure ports P2 and P1 (B).  Spatial and temporal thrombus 
development was monitored by side-view imaging at controlled wall shear rates and ΔP. 
Platelet (red) and P-selectin (green) were imaged to investigate spatial differences in 
platelet activation under physiologic flow conditions (C).  A fluorogenic, thrombin 
cleavable substrate Boc-VPR-AMC was added to whole blood to demonstrate localized 
thrombin activity within clots developed in the presence of ΔP (D). 
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4.3.2 Transthrombus pressure gradients influence thrombin mediated clot growth at 
400 s-1 
Thrombin mediated clot growth was investigated by perfusing CTI-treated whole 
blood over a collagen/TF scaffold at 400 s-1.  Transthrombus pressure gradients were 
maintained at either a low (9.0 mm Hg) or high ΔP (29.4 mm Hg).  Total platelet area 
was calculated at each time point over the duration of the experiment (t=10.8 min).  Clots 
developing at lower ΔP (9.0 mm Hg) experienced faster initial growth (~3.8 fold faster, 
t=0-1.8 min, P<0.05) and larger final heights (~1.5 fold larger, t=10.5 min, P<0.025) than 
clots experiencing higher ΔP (29.4 mm Hg) (Figure 4-3A).  The P-selectin (core) area 
was 57% of the total clot area for both low and high ΔP (Figure 4-3B).  While % core 
remained constant, final core area was reduced by 33% (P<0.05) when ΔP was increased.  
Similar trends were observed when measurements were made with a thrombin sensing 
antibody.  Final thrombin area was reduced by 43% (P<0.05) when ΔP was increased 3.2 
fold (Figure 4-3C).  This result indicates that the elution of inner clot thrombin to the 
surface of the clot was met with opposition by pressure-driven permeation of fluid 
through the clot, towards the “extravascular” space (the collagen post array).  When 
trans-clot pressure drops were increased, the permeation-mediated transport through the 
clot also increased proportionately. This reduced thrombin transport towards the clot 
surface to result in a smaller core area.  Thrombin and P-selectin area were highly 
correlated both spatially and temporally at low ΔP (R2=0.91) and high ΔP (R2=0.95) 
(Figure 4-3D).  Reducing the permeation by decreasing ΔP results in greater flux of 
thrombin from the collagen/TF interface through the clot toward the lumen, thus resulting 
in a larger P-selectin positive core at lower ΔP.    
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Figure 4-3 Transthrombus pressure gradients reduce clot size by diminishing 
thrombin boundary growth. 
Platelet area was measured for clots (n=3) formed at a constant wall shear rate (400 s-1) in 
the presence of either a low (ΔP=9.0 mm Hg) or high (ΔP=29.4 mm Hg) transthrombus 
pressure gradient (A).  Clot architecture was investigated by measuring intrathrombus P-
selectin (B) and thrombin (C) area for each condition.  The correlation between platelet 
activation marker P-selectin and thrombin area were quantified for each condition over 
the duration of the experiment (t=10.8 min) (D).  
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4.3.3 Fibrin polymerization reduces both total platelet and core area at 400 s-1 
Fibrin polymerization has been recognized as an important step in clot 
stabilization and the prevention of embolic events [48].  Beyond this role, less is known 
about what impact fibrin polymerization may have on clot architecture and regulation of 
clot growth rate.  In order to study these effects on thrombus growth and architecture we 
added GPRP, a fibrin polymerization inhibitor.  Whole blood anticoagulated with CTI 
was incubated with and without GPRP prior to perfusion (400 s-1) over a collagen/TF 
surface.  All clots were developed in the presence of a constant transthrombus pressure 
gradient (Control-ΔP = 20 ± 0.7 mm Hg, GPRP- ΔP= 20 ± 0.5 mm Hg).  Thrombus 
growth and architecture (P-selectin, fibrin) were monitored dynamically for 10.5 min of 
perfusion.  Total platelet area and clot height grew to a greater extent when fibrin 
polymerization was inhibited by 5 mM GPRP (Figure 4-4A).  Following 3 min of 
growth, clots formed in the presence of polymerized fibrin were statistically smaller 
(P<0.05) than clots formed without polymerized fibrin.  Disparity between clot size 
became even greater following 5.25 min (P<0.025).  Final clot height (t=10.5 min) was 
67% (P=4.95x10-5) larger when fibrin polymerization was inhibited.   Accompanying 
total clot growth was an increase in core area (Figure 4-4B).  P-selectin positive area 
grew 2-fold larger (P=0.003) when fibrin polymerization was absent.  As expected, fibrin 
polymerization, as measured by a fibrin specific antibody, was completely abolished by 5 
mM GPRP (Figure 4-4C).  The growth of fibrin slightly preceded the P-selectin positive 
core development in the control clots (no GPRP).  This indicated that fibrin 
polymerization was responsible for mitigating core development and total clot growth at 
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400 s-1, a phenomena that was not observed when thrombin was inhibited with PPACK 
(Figure 4-5). 
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Figure 4-4 Fibrin polymerization reduces clot growth at a wall shear rate of 400 
s-1 and ΔP=20 mm Hg.   
Platelet area (n=7, A) was measured in the absence (control) and presence (5 mM GPRP) 
of fibrin polymerization inhibitor Gly-Pro-Arg-Pro at a constant transthrombus pressure 
gradient (ΔP=20 mm Hg) and wall shear rate (400 s-1).  P-selectin (n=7, B) and fibrin 
(n=4, C) area were monitored for each condition during 10.5 min of CTI whole blood 
perfusion.  
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Figure 4-5 GPRP has no effect on the total clot or P-selectin (core) area when 
thrombin is inhibited. 
Whole blood perfused at 400 s-1 was treated with PPACK/Apixaban/CTI to prevent 
thrombin generation and activity.  Total clot and P-selectin (core) area were investigated 
in the presence and absence of 5 mM GPRP. 
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4.3.4 Wall shear rate does not influence the core or thrombin area but does 
influence the role of fibrin 
Since our device facilitated independent control of both wall shear rate and 
transthrombus pressure gradients, we investigated clot architecture at constant ΔP (20 
mm Hg) for three shear rates (100 s-1, 400 s-1, 2000 s-1) ranging from venous to arterial 
flows.  Total clot, core, thrombin and shell area were measured for 10.5 min of whole 
blood perfusion.  The final area (t=10.5 min) for each were reported at the three distinct 
shear rates (Figure 4-6A).  Interestingly, wall shear rate did not significantly alter the 
core or thrombin area when the trans-clot ΔP was held constant at 20 mm Hg.  The only 
significant change that wall shear rate influenced was the shell size.  The shell size was 
greatest at a venous shear rate of 100 s-1 as compared to 400 s-1 (P=0.026) and 2000 s-1 
(P=0.007).  This increased shell thickness resulted in an increase in total clot size at 100 
s-1 (P=0.009 for 400 s-1; P=0.015 for 2000 s-1).  These outcomes indicated that shear rate 
only influences shell size while the transthrombus pressure gradient influences both core 
and thrombin boundary size (Figure 4-3 and Figure 4-6). 
Clots in the presence of GPRP were developed in parallel with control clots for 
each shear rate.  The blockade of fibrin polymerization on total clot, core, thrombin, and 
shell area was investigated at the final time point (t=10.5 min) (Figure 4-6B).  Based on 
our previous results at 400 s-1 (Figure 4-4), we expected GPRP blockade of fibrin 
polymerization to enhance clot height and core area at both venous and arterial shear 
rates.  This expectation was confirmed for an arterial shear rate of 2000 s-1 (Figure 
4-6C).  The addition of GPRP significantly increased total clot area (1.45-fold for 400 s-1, 
1.5-fold for 2000 s-1) due to a drastic increase in core area (2.0-fold for 400 s-1, 1.65-fold 
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for 2000 s-1).  The increase in core area was directly proportional to a significant increase 
in thrombin area at both 400 s-1 (108% increase) and 2000 s-1 (87% increase).  
Interestingly, clots developed at the venous shear rate of 100 s-1 did not increase in total 
clot, core, or thrombin area when fibrin polymerization was inhibited with GPRP.  These 
results indicated that thrombin regulation in venous clots is not governed by fibrin 
polymerization.  
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Figure 4-6 Wall shear rate does not change the core or thrombin area but does 
influence thrombin mediated clot growth in the absence of fibrin 
polymerization.   
Total, core (p-sel+), thrombin, and shell (p-sel-) areas were measured, at the final time 
point (t=10.5 min), for clots developed at a constant pressure gradient (ΔP=20 mm Hg) 
and varying wall shear rate (100 s-1, 400 s-1, 2000 s-1) (n=4 for each shear rate) (A).  CTI 
whole blood in the presence of 5 mM GPRP (fibrin polymerization inhibitor) was run in 
parallel at all experimental conditions (n=4 for each shear rate) (B).  The fold increase in 
area with the addition of 5 mM GPRP was calculated for total, core, thrombin, and shell 
area (C). 
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4.3.5 ’ fibrin(ogen) reduces thrombin mediated clot growth at venous shear rates 
but not arterial shear rates 
In order to further investigate the role of fibrin(ogen) in venous and arterial clot 
growth, we added a monoclonal ’-fibrinogen specific antibody to inhibit the high affinity 
thrombin binding site on ’-fibrinogen (Figure 4-7).  Antibodies were incubated in CTI 
whole blood at a 1:1 molar ratio to 0.3 mg/ml ’ fibrinogen, a physiologically relevant 
whole blood concentration [87].  Control and ’ antibody treated samples were perfused 
simultaneously at both 100 s-1 and 2000 s-1.  Total clot, core, and thrombin area were 
measured dynamically at a constant trans-clot ΔP (control ΔP=15.5 mm Hg, ’ antibody 
ΔP=15.7 mm Hg). Clots formed at the venous shear rate of 100 s-1 had significantly 
increased total clot area, core area, and thrombin area when the high affinity thrombin 
binding site on ’ fibrinogen was blocked (Figure 4-8, first column).  Total clot area 
after 11.25 min of whole blood perfusion was 2.0 fold larger (P=0.019) in the presence of 
the ’ fibrinogen antibody.  This increase in total clot area was associated with faster core 
(1.5 min) and thrombin generation (1.25 min) and larger final areas (core-1.8 fold, 
thrombin-1.6 fold).  Conversely, there were no significant differences between thrombi 
formed at the arterial shear rate of 2000 s-1 (Figure 4-8, second column). 
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Figure 4-7 γ’-fibrinogen binds more thrombin and is inhibited to a greater extent 
than γA-fibrinogen (free of the γ’-chain).   
Wells in a 384 well plate were coated with either γ’-fibrinogen or γA-fibrinogen.  After 
rinsing and blocking non-coated surfaces with BSA, a monoclonal γ’-fibrinogen specific 
antibody was added to half of the γ’-fibrinogen wells and half of the γA-fibrinogen wells.  
Excess antibody was removed and thrombin was incubated in each well.  Following 
another rinse, a thrombin cleavable substrate (Boc-VPR-AMC) was added to each well 
and cleavage was followed using spectrofluorometry.   
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Figure 4-8 Inhibition of ’ fibrin(ogen) with a ’ specific monoclonal antibody 
results in larger clots at venous but not arterial shear rates.   
Whole blood anticoagulated with CTI ± ’ mAb was perfused over a collagen/TF scaffold 
at a constant transthrombus pressure gradient (control ΔP=15.5 mm Hg, ’ antibody 
ΔP=15.7 mm Hg).  Total, core (p-sel+), and thrombin area were measured dynamically at 
both venous (100 s-1, first column, n=3) and arterial (2000 s-1, second column, n=3) 
shear rates throughout the duration of the experiment. 
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4.3.6 Arterial shear rates promote increased platelet packing, greater thrombin 
retention, and more fibrin generation per area than venous shear rates 
Since clots formed at venous and arterial shear rates demonstrated inverse growth 
patterns when fibrin polymerization or the high affinity thrombin binding site on ’ 
fibrinogen were blocked, we hypothesized that clot composition may influence 
fibrin(ogen)’s role in thrombin regulation. We investigated platelet packing density 
(Figure 4-9A), density corrected thrombin sensor cleavage (Figure 4-9B), and fibrin 
packing density (Figure 4-9C) by comparing clots formed in CTI whole blood at 100 s-1 
to those formed at 2000 s-1.  Representative images at the final time point (t=11.5 min) 
demonstrated increased platelet packing at 2000 s-1 as compared to 100 s-1.  Likewise, 
density corrected thrombin sensor cleavage and fibrin packing density were also 
increased at arterial shear rates (2000 s-1) as compared to venous shear rates (100 s-1).  
The fold increase in platelet packing density as measured by platelet fluorescence 
intensity per area was on average 1.83 fold higher at 2000 s-1 than 100 s-1 (Figure 4-9D).  
After normalizing the thrombin sensor fluorescence intensity for platelet density, the 
results indicated that more sensor was cleaved in arterial clots than venous clots (1.4 
fold).    This provides a lower estimate for the relative increase in thrombin activity in 
arterial clots compared to venous clots.  Supporting this estimate was the increased 
generation of fibrin in arterial clots (2.36-fold).  These results demonstrated a drastic and 
important difference in the composition of clots formed at arterial or venous shear rates.  
  
103 
 
 
Figure 4-9 Clots formed at arterial shear rates pack tighter, cleave more 
thrombin sensitive peptide per area, and generate more fibrin per 
area than venous clots.   
CTI whole blood was perfused simultaneously at a venous shear rate of 100 s-1 and an 
arterial shear rate of 2000 s-1.  Platelet (A), normalized thrombin sensor (B), and fibrin 
fluorescence intensity (C) were imaged for 11.5 min.  The fold increase in platelet 
fluorescence intensity per area (n=6) from clots formed at 100 s-1 compared to 2000 s-1 
was averaged over the duration of the experiment (D).  In addition, the density corrected 
thrombin sensor cleavage (n=6) and fibrin fluorescence intensity (n=3) were calculated 
and compared for venous and arterial clots. 
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4.3.7 Fibrin polymerization reduces clot growth at pathological shear rates 
In pathophysiology, wall shear rates can reach 100,000 s-1 in stenosed vessels 
[24].  We investigated clot formation in a scenario similar to vessel stenosis by stepping 
the wall shear rate up from an initial venous shear rate of 200 s-1 to a pathological shear 
rate of 15,000 s-1.  Clots were formed in PPACK whole blood at 200 s-1 for 7 min before 
stepping the shear rate up to 15,000 s-1 for an additional 7.75 min (Figure 4-10A-C).  
Following the increase to pathological shear rates, rapid platelet aggregation at the 
upstream edge of the clot resulted in a low shear regime prior to the trailing edge of the 
clot.  The low shear regime facilitated the accumulation of ADP and TXA2 agonists.  
This was evident by the clot contraction at the downstream edge of the clot (Figure 
4-10C), a flow sensing mechanism that we previously documented when shear rates were 
reduced [46].  In this experiment, the contraction towards the center of the clot was not 
prevented, even at 15,000 s-1. 
The role of fibrin polymerization was also investigated at pathological shear rates.  
Whole blood anticoagulated with either CTI or PPACK was perfused across a 
collagen/TF or collagen surface respectively.  Experiments were performed 
simultaneously with both control and GPRP treated samples in order to evaluate the role 
of fibrin polymerization.  The blood was initially perfused at an arterial shear rate of 2000 
s-1.  After 5.4 min, the wall shear rate was increased to a pathological shear rate of 15,000 
s-1 for the remaining 5.8 min of the experiment.  The inhibition of fibrin polymerization 
with GPRP in CTI whole blood resulted in increased clot growth for both arterial and 
pathological shear rates (Figure 4-10D).  The average clot height of GPRP clots was 
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73.2% larger after 5.4 min of flow at 2000 s-1 (P=0.006) and 152.4% larger after an 
additional 5.8 min of flow at 15,000 s-1 (P=0.001).  In contrast, PPACK whole blood 
clots did not demonstrate a significant increase (P>0.05) with the addition of GPRP at 
either arterial or pathological shear rates (Figure 4-10E).  This demonstrated a specific 
effect on clot growth due to the inhibition of fibrin polymerization and not off target 
effects. 
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Figure 4-10 Clot growth at pathological shear rates was abated by fibrin 
polymerization.   
PPACK whole blood was perfused across a collagen scaffold at 200 s-1.  Clot formation 
was imaged with a fluorescent platelet specific monoclonal antibody (red) (A).  
Following 7 min of perfusion, the shear rate was increased to a pathological shear rate of 
15,000 s-1.  Images of clot formation were taken at t=10.75 min (B), and t=14.75 min (C).  
Zones of low shear, caused by rapid platelet aggregation upstream, often formed and 
contracted at the trailing edge of the developing clot.  In a similar experiment either CTI 
or PPACK whole blood was perfused over a collagen/TF or collagen surface 
respectively.  Perfusion was initially at 2000 s-1 prior to stepping the shear up to 15,000 s-
1.  Control conditions were compared to GPRP treated samples with inhibited fibrin 
polymerization.  Clot height was recorded throughout the duration of the experiment (D).  
Average clot heights were calculated for both the control and GPRP samples.  The 
measurements were made for both CTI (n=4 each condition) and PPACK (n=4 each 
condition) treated whole blood both before and after increasing the shear rate (E). (*, 
P<0.01) 
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4.4 Discussion 
The clots developed in our device utilizing human blood (Figure 4-11A), closely 
matched the architecture of clots developed in vivo (Figure 4-11B).  When the device 
was operated at a constant wall shear stress, we observed that transthrombus pressure 
gradients could regulate the core and thrombin heights.  Reducing transthrombus pressure 
gradients resulted in an increase in the core and thrombin heights, leading to larger total 
clot heights.  In this scenario, pressure driven permeation through the clot towards the 
extravascular space was reduced when ΔP was reduced.  This decrease in permeation 
toward the extravascular space allows for thrombin diffusion through the clot towards the 
lumen.  As the thrombin boundary grew, the core region grew.  In turn, this may result in 
an increase in ADP and TXA2 release as demonstrated by P-selectin exposure.  Since 
ADP and TXA2 are soluble small molecules and diffuse much faster than thrombin 
(DADP=50x10
-11 m2/s >> DThrombin=8x10
-11 m2/s), they facilitated shell growth by 
recruiting additional platelets to the surface of the clot (Figure 4-11C) [91, 92]. 
We demonstrated that the core/shell architecture was present throughout the 
development of human blood clots under physiologic conditions of hemostasis over an ex 
vivo wound of collagen/TF. The sensitivity of the core and shell development was 
investigated by independently controlling the wall shear rate (100 s-1 to 2000 s-1) and 
transthrombus pressure gradient (ΔP=9.0 to 29.4 mm Hg).  Fibrin polymerization reduced 
thrombin mediated clot growth at arterial but not venous shear rates.  This can be 
explained by our observation of increased platelet and fibrin packing at arterial shear 
rates as compared to venous shear rates. The influence of the shear rate on clot structure 
108 
 
and composition became more evident when ’-fibrinogen’s high affinity thrombin 
binding site was inhibited with a monoclonal antibody.  When clots were developed at 
venous shear rates (decreased packing density) and the high affinity thrombin binding site 
on A/’ was inhibited, the size of the total clot, thrombin, and core increased. 
We also demonstrated that the shell region is dependent on the local shear rate at 
the surface of the clot whereas the core region is only a dependent on the transthrombus 
pressure gradient.  These results agree with the governing role of transport rates within 
and around the developing clot.  The low permeability of thrombi places an emphasis on 
both convective and diffusive transport within the clot while the transport at the surface 
of the clot is governed by the local wall shear rate (convection>>diffusion) [86].  This 
means that thrombin, which has a much slower diffusion rate than ADP or TXA2, 
requires the protection of the clot to effectively diffuse.  Conversely, the diffusive 
transport rates of ADP and TXA2 are fast and can compete with larger convective forces 
that are present near the surface of the clot.  This is why shell growth has been directly 
correlated with ADP and TXA2 [27].   So when surface convection rates are low, such as 
venous shear rates, ADP and TXA2 diffusion plays a larger role in platelet recruitment.  
This role is diminished at arterial shear rates which causes reduced shell growth.  These 
results define the physical parameters that govern clot development and the resulting core 
and shell architecture of human clots. 
Another important aspect of clot development is fibrin formation.  In order to 
study fibrin’s role, we examined the packing density of platelets and fibrin within human 
thrombi formed at venous or arterial shear rates.  We found that increasing the shear from 
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a venous to an arterial rate results in an increase in both platelet and fibrin packing. We 
also found an increase in thrombin activity at arterial shears. These results supported 
previous work performed in vivo, which described the majority of fibrin formation as 
being contained within the densely packed core [27, 73, 75].  Complementary in silico 
investigations using the porosities of the tightly packed core and loosely packed shell 
illustrated thrombin retention within the core region due to the lower porosity decreasing 
the effective diffusion of thrombin [74]. 
To determine how fibrin contributes to the formation of a dense clot 
microenvironment we formed clots in the presence of GPRP to prevent fibrin 
polymerization. Our results demonstrated a drastic increase in thrombin, core, and total 
platelet area when fibrin polymerization was inhibited with GPRP at arterial shear rates.  
The same increase was not observed at venous shear rates, where clot porosity was 
elevated and fibrin density was reduced.  At arterial shears our results are consistent with 
increased thrombin diffusion due to a lack of fibrin leading to an increased area of 
activity.  However, in the case of clots generated at venous shear rates that have high 
porosity we propose that the reduced fibrin facilitated rapid convective removal of 
thrombin through the injury site.  As a result, the removal of fibrin polymerization 
facilitated even greater thrombin removal, causing mild reductions in total and thrombin 
area.  We hypothesized that thrombin diffusion towards the vessel lumen may also be 
limited by binding rather than just physical hindrance. 
We investigated this hypothesis by preventing thrombin binding to the high 
affinity binding site on the ’-chain of fibrinogen.  The ’-chain has been implicated as a 
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new clinical biomarker for acute events and chronic diseases such as myocardial 
infarctions, coronary artery disease, and deep vein thrombosis [87, 93, 94].  Studies have 
shown that thicker fibrin fibers (low thrombin concentrations) have more ’ binding sites 
than thinner fibrin fibers (high thrombin concentrations) [95].  These reports, coupled 
with our thrombin sensor cleavage results, predict greater ’-thrombin binding at venous 
shear rates rather than arterial shear rates due to the differences in the fibrin network.  
When we blocked the high affinity binding site on the ’-chain of fibrinogen with a 
monoclonal antibody we saw significant increases in total clot, thrombin and core area 
only at venous shear rates.  This suggests that at venous shear rates, fibrinogen 
preferentially binds thrombin using the ’-chain of fibrinogen to inhibit thrombosis.  
Conversely, the low porosity and increased fibrin present in arterial clots prevents 
thrombin boundary growth by physically limiting the diffusion of thrombin.  While 
thrombin binding to A/’ is still present, it alone cannot prevent thrombin mediated clot 
growth at arterial shear rates.  These results complement the requirement of fibrin 
polymerization at arterial and not venous shear rates. 
Interestingly, clots formed at pathological shear rates were also dependent on 
fibrin polymerization for regulated growth.  We investigated this dependence by 
increasing the wall shear rate from an arterial shear rate (2000 s-1) to a pathological shear 
rate (15,000 s-1) that might be found in a stenosed vessel.  When the control samples were 
compared to the GPRP treated samples, the results demonstrated that fibrin 
polymerization was responsible for the reduction in clot growth at pathological shear 
rates.  This regulation was in align with our results at arterial shears.  Increasing the shear 
111 
 
rate from an arterial to pathological rate increases the dependence on platelet-vWF 
interactions [96].  In this case, fibrin limits thrombin mediated platelet recruitment and 
may also interfere with platelet-vWF interactions necessary for growth at pathological 
shears.  This is evident by the increased growth in PPACK samples void of fibrin.  This 
mechanism may be protective in the event of a ruptured plaque where tissue factor 
exposure and shear rates are high [97].  In a similar experiment, the wall shear rate was 
increased from a venous shear and whole blood was anticoagulated with PPACK.  The 
clot grew rapidly, at the leading edge, when shears were increased to pathological rates.  
This rapid growth created a zone of low shear which facilitated the local accumulation of 
soluble agonists such as ADP and TXA2, as we have previously demonstrated [46].  This 
enabled the downstream edge of the clot to contract, a flow sensing response to anchor 
the clot to the collagen scaffold.  The contraction in the opposite direction of a 
pathological shear rate of 15,000 s-1 was strong enough to prevent embolization in the 
absence of fibrin. 
While the venous and arterial clots in this study were investigated at the same ΔP, 
lower vessel pressures are often found in venous circulation as compared to arterial 
circulation [23].  This reduction in vessel pressure may decrease the pressure drop across 
the developing clot, which would allow greater thrombin boundary growth and fibrin 
formation.  The increase in fibrin formation along with the trapping of red blood cells 
gives venous clots the label of ‘red clot’.  On the other hand, arteries often have a higher 
vessel pressure than veins which may increase the transthrombus pressure gradient which 
would decrease clot retention of thrombin and the formation of fibrin.  This reduction in 
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fibrin and the high concentration of platelets gives arterial clots the label of ‘white clot’.  
As we have demonstrated these changes in transthrombus pressure gradients would 
increase the role of thrombin binding via ’ fibrinogen and decrease fibrin’s role in 
hindering thrombin diffusion because of the resulting increase in convective removal.  
These observations illustrate the complex balance of both physical and biochemical 
parameters that influence the development of clots (Figure 4-11C). 
These results have numerous clinical implications, particularly in venous and 
arterial thrombosis. Recent reports of interest have shown that IL-6 disproportionately 
increases the expression of ’ as compared to A [98].  Elevated IL-6 levels are 
associated with increased risk of future MI [99].  The increase in ’-chain fibrinogen 
seems to be a mechanism for protection, at least in the venous circulation.  Our results in 
this study did not indicate any protective effects within clots generated at arterial 
conditions but did show protective effects at venous shear rates.  This may explain why 
lower ’ levels have been implicated as a DVT risk [94].  Future work to determine the 
function of the core/shell architecture and role of ’-fibrinogen in different 
pathophysiologies will be required to advance and improve patient care. 
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Figure 4-11 Human thrombi develop a core and shell architecture that mimic the 
architecture of clots developed in vivo.   
Human clots developed in vitro (A) and mouse clots developed in vivo (B) were outlined 
by imaging the clots using platelet (blue) and P-selectin antibodies (red).  A heat map was 
used in both images to illustrate the localization of thrombin sensor cleavage (light blue = 
low intensity and white = high intensity).  A schematic representing the regulation of 
thrombin and small molecules ADP and TXA2 demonstrates both the physical and 
biochemical transport regulations observed within clots (C). (ε, porosity; k, permeability, 
D, diffusivity, p*, activated platelet) 
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Chapter 5 : Rapid on-chip recalcification and drug dosing of citrated whole blood 
using microfluidic sheath flow 
5.1 Introduction 
Exposure of extracellular matrix (ECM) proteins at a site of vascular injury elicits 
a hemostatic response from both platelets and coagulation proteins.  Primary hemostasis 
or platelet plug formation is simultaneously accompanied by the generation of thrombin 
and fibrin via the coagulation cascade [1].  One factor in this response is the local wall 
shear stress (τw).  Blood experiences both high (arterial) and low (venous) shear stress as 
it flows throughout the vasculature [23].  In cylindrical vessels, wall shear stress is 
uniform around the circumference of the vessel.  Recreating this constant shear stress at 
an injury site in a rectangular microfluidic channel is difficult due to the corners.  
Sheathing the blood flow from the corners may result in an injury with a more 
physiologic architecture while offering an opportunity to diffuse small molecules into the 
blood via the sheathing buffer. 
Platelet and coagulation assays most commonly require whole blood to be drawn 
directly into sodium citrate, an anticoagulant that chelates Ca2+ [101, 102].  Prior to most 
clinical assays such as PT and aPTT, citrated blood is recalcified to restore platelet and 
coagulation function [103, 104].  Unfortunately, many microfluidic or flow assays 
neglect recalcification prior to flow [105].  While previous microfluidic assays have 
demonstrated platelet and coagulation function under various shear rates and pressure 
gradients [46, 86], there have been a limited number of microfluidic studies focusing on 
the recalcification of citrated whole blood and the resulting platelet and coagulation 
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function under flow conditions.  These experiments are important because of the clinical 
use of citrated whole blood and the recent advances in assays utilizing flow such as the 
PFA-100.  This assay measures the time required for citrated whole blood to close a 
narrow opening in a collagen membrane.  Without recalcification, the citrated blood used 
in the PFA-100 limits the system measurement to only platelet dysfunction [106].  
Currently, there are no devices capable of reproducing the recalcification of citrated 
whole blood and evaluating the effects on platelet and coagulation function under flow 
conditions.  A device capable of these characteristics would be important for clinically 
relevant flow assays utilizing citrated whole blood. 
We describe the design and characterization of a converging trifurcation 
microfluidic device capable of recalcifying or drug-dosing whole blood under flow 
conditions.  The device permits measurements of platelet and coagulation function at 
varying levels of recalcification or platelet inhibition along the length of the channel.  
Localized collagen or collagen/tissue factor (TF) surfaces initiated platelet and 
coagulation responses at a constant wall shear stress.  This was produced by sheathing 
anticoagulated whole blood with buffer (±Ca2+).  During recalcification of citrated whole 
blood, both platelet and coagulation response demonstrated a dependence on the 
reconstitution of calcium.  Citrated whole blood incubated for longer times prior to 
recalcification resulted in a priming of the intrinsic pathway (due to Factor XIIa 
generation in the absence of calcium). Both platelet and coagulation responses were 
initiated faster and magnified at the final time point.  The addition of MRS-2179, a 
platelet P2Y1 antagonist, to the buffer sheath flow resulted in a dose dependent inhibition 
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of platelet deposition in a single channel.  The calculated IC50 for this dose response 
correlated well with previous reports.  The device we report demonstrates the ability to 
recalcify citrated whole blood under flow as well as the ability to provide accurate single 
channel measurements of platelet antagonist IC50 values.  This is the first device we have 
knowledge of that can provide both of these characteristics. 
5.2 Materials and Methods 
5.2.1 Fabrication 
Silicon wafers (D = 100 mm, WRS Materials) were spin coated with a 60 µm 
layer of negative photoresist (KMPR 1050, MicroChem Corp.).  Following a 20 min soft 
bake and UV exposure, the substrate was baked for an additional 4 min at 100 °C.  The 
wafer was then developed using AZ® 300 MIF (AZ Electronic Materials USA Corp.).  
Devices were fabricated using polydimethylsiloxane (PDMS) (Ellsworth Adhesives) at a 
10 : 1 ratio of base to curing agent.  All inlet and outlet ports were cored using 0.75 mm 
I.D. corers (Harris Uni-Core™, Ted Pella, Inc.).  Connections between the PDMS 
devices and 250 μL syringes (Hamilton Company) were made using 90°, 23 gauge x 1/2” 
length blunt needles (Small Parts) and 0.020” ID x 0.060” OD tubing (Cole-Parmer).  
Devices were reversibly sealed to the glass slides using a vacuum pump and the 
previously mentioned tubing. 
5.2.2 Design 
The trifurcation device utilized in these studies was designed to sheath whole 
blood with buffer flows.  The device consisted of three inlets and one outlet.  The center 
inlet is described as the blood inlet and the two side inlets are described as the buffer 
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inlets.  The blood entrance length and buffer entrance lengths were 3 mm and 1.8 mm 
respectively.  Channel widths were 250 μm for the blood inlet and 110 μm for the buffer 
inlets.  At the trifurcation point, the buffer inlets were introduced at a 20° angle to the 
blood inlet.  Following the trifurcation of the three inlets (RBlood= 1000 μm, RBuffer=750 
μm), the channel widened to 300 μm.  The channel was 44.8 mm in length and exited at a 
single outlet (RExit=1000 μm).  Each chip was designed with two channels parallel to each 
other separated by 8 mm.  Surrounding the channels were designed post regions 
(RPost=500 μm) to support vacuum sealing of the chips to glass slides (75 mm x 38 mm, 
Fisher Scientific). 
In addition to the trifurcation device, protein patterning devices were also 
designed.  These devices used the same dimensions as the trifurcation template to provide 
patterned strips at consistent distances from the trifurcation point.  Two patterning 
devices were utilized, one with 7 channels and another with 8 channels.  Both the 7 
channel and 8 channel devices were designed with 250 µm channels perpendicular to the 
direction of the trifurcation flow with one inlet (R=1000 μm) and one outlet (R=1000 
μm).  The channels were 11 mm in length and separated by 6 mm (7 channel design) or 
5.5 mm (8 channel design).  This feature allowed one device to pattern protein at one or 
more locations on two independent trifurcation channels.  Similar to the trifurcation 
device, the patterning devices were designed with post regions to support vacuum 
assisted sealing to the glass slide.  
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5.2.3 Blood Collection 
Phlebotomy was performed in accordance with the University of Pennsylvania’s 
IRB.  Human blood was collected from healthy volunteers, self reporting as alcohol and 
medication free.  Blood was anticoagulated with 100 µM Phe-Pro-Arg-
chloromethylketone (PPACK) (Haematologic Technologies Inc.) or concentrated citrate 
solution (1 part anticoagulant to 9 parts whole blood) (Sigma-Aldrich).  Citrated whole 
blood was occasionally supplemented with 40 μg ml-1 corn trypsin inhibitor (CTI) 
(Haematologic Technologies Inc.).  Studies devoid of TF utilized PPACK whole blood 
and 1 µg ml-1 of a fluorescently conjugated anti-CD41 monoclonal antibody (Abd 
Serotec).  Studies including thrombin utilized citrated whole blood ± CTI.  These samples 
were prepared with the previously mentioned anti-CD41 monoclonal antibody as well as 
0.0125 mg ml-1 of a fluorescently conjugated fibrinogen (Invitrogen). 
5.2.4 Operation 
Glass slides were treated with Sigmacote® (Sigma-Aldrich) to impede blood 
clotting and the adsorption of basic proteins.  Following surface treatment, a patterning 
device was vacuum sealed to the slide.  Collagen (Chrono-log Corp.) was patterned on 
the slides by pulling the solution through the desired channel(s).  Immediately afterwards, 
0.5% bovine serum albumin (BSA) was rinsed through the channel(s) to remove free 
collagen.  In experiments requiring tissue factor (TF), the patterned collagen was 
incubated with TF solution (Dade Innovin Reagent, Siemens) following the BSA rinse.  
After incubating for 30 min, the channel was rinsed with 0.5% BSA and the patterning 
device was removed. 
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The trifurcation device was placed directly on top of the patterned collagen.  The 
horizontal edge was aligned with the glass slide and the vertical edge was aligned to fit 
both flow channels perpendicular to the patterned collagen.  Syringes were loaded with 
anticoagulated whole blood and HEPES buffer (HBS) supplemented with methyl 
cellulose (0.02%, Sigma-Aldrich).  The addition of methyl cellulose increased the buffer 
viscosity to the same viscosity as whole blood (3 cP) [47].  In experiments investigating 
dye diffusion, fluorescein isothiocyanate (FITC) (Sigma-Aldrich) was loaded in the 
sheath buffer and Texas Red® conjugated albumin (BSA) (Invitrogen) was loaded in the 
blood or buffer in the center inlet.  Recalcification experiments used buffer loaded with 
30 mM Ca2+ while drug dosing experiments used buffer with physiologic calcium 
concentrations (2.4 mM Ca2+) and 10 µM MRS-2179 (Tocris Bioscience), a potent P2Y1 
inhibitor [107]. 
A constant volume syringe pump (PHD Ultra, Harvard Apparatus) was used to 
perfuse the anticoagulated whole blood syringe as well as both buffer syringes.  The 
equal flow rates set the width of each fluid to 100 µm with the center inlet containing the 
whole blood and the two side inlets containing buffer.  Wall shear rate was controlled by 
adjusting the flow rate appropriately.  All experiments in this study were performed at 
room temperature and set at a constant wall shear rate (600 s-1).  Glass slides with 
vacuum sealed devices were positioned on an inverted microscope (IX81) (Olympus 
America Inc.) and imaged with an ORCA-ER CCD camera (Hamamatsu). 
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5.2.5 Finite Element Analysis 
COMSOL Multiphysics was used to simulate fluid flow and solute transport 
within the trifurcation device.  Laminar fluid flow was modeled using the stationary 
Navier-Stokes equation while the solute transport was modeled using the conservation 
equation for chemical species.  Both blood and buffer were defined with equal viscosity 
(µ=3 cP) and density (ρ=1060 kg m-3).  Diffusion coefficients were defined for FITC 
(DFITC= 6.4 x 10
-10 m2 s-1 in water) [108], BSA (DBSA= 6.1 x 10
-11 m2 s-1 in sodium 
phosphate/chloride buffer) [109], and calcium (DCa2+= 7.9 x 10
-10 m2 s-1 in water) [110] 
after they were adjusted using the Stokes-Einstein Relation to account for the increased 
viscosity of blood/buffer (µ=3 cP).  Additionally, the diffusion coefficient for MRS-2179 
(DMRS-2179= 1.5 x 10
-10 m2 s-1, µ=3 cP) (Stokes-Einstein Relation) was defined and the 
flow rates for blood/buffer were set (Q=1.91 μL min-1).  The model was validated by 
simulating the normalized area under the curve in the middle 100 μm of the channel for 
both FITC and BSA diffusion.  Simulated values were collected along the length of the 
channel and compared to experimental measurements.  The validated model was used to 
predict calcium and MRS-2179 diffusion along the length of the channel for a wall shear 
rate of 600 s-1.  All simulations were performed with a 2D model using a shallow channel 
approximation with a thickness equal to the height of the microfluidic channel (h=60 
µm).  The approximation allowed the model to simulate the conditions at the center of the 
channel in the z-direction (h=30 µm), where all experimental measurements of the 
fluorescent species were imaged. 
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5.3 Results 
5.3.1 Diffusion controlled recalcification of citrated whole blood 
We designed a trifurcated microfluidic device to analyze platelet and coagulation 
function at a controlled wall shear stress (Figure 5-1A).  The center channel and two side 
channels were simultaneously perfused with citrated whole blood and 30 mM Ca2+ buffer 
(μ = 3 cP) respectively (Figure 5-1B).  The calcium buffer sheathed the blood flow 
which prevented the blood from contacting the patterned collagen/TF surface near the 
corners of the channel, where τw = 0 dynes/cm
2.  Instead, the wall shear stress 
experienced by the blood remained constant (Figure 5-2), while the buffer shear stress 
diminished as it approached the corners.  This flow design enabled the constant wall 
shear stress found in cylindrical capillaries or veins to be recreated in a rectangular 
microfluidic device. 
At the trifurcation entrance, the buffer and blood streams merged as illustrated 
with FITC dye (Figure 5-1C) and a COMSOL simulation predicting Ca2+ diffusion 
(Figure 5-1D).  The 20° entrance angle and laminar fluid flow (Re=0.14) produced sharp 
interfaces between the blood and buffer.  The low Reynolds number flows associated 
with microfluidic devices minimized convective mixing [111].  Therefore, diffusion 
controlled the concentration gradients found across the blood and buffer flows.  FITC dye 
was added to the buffer flow stream and the concentration in the middle 100 μm of the 
channel was measured in whole blood or buffer.  The normalized area was determined 
along the length of the channel (Figure 5-1E).  At 42 mm downstream of the trifurcation 
entrance, 62.5% of the maximum dye area was obtained in whole blood.  The COMSOL 
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simulation recreating this experiment predicted this measurement within 0.5%.  In a 
similar experiment, Texas Red® conjugated BSA was added to whole blood or buffer in 
the center flow stream.  Measurements of the normalized BSA area in the middle 100 μm 
of the channel were made along the length of the channel (Figure 5-1F).  Only 17.7% of 
the maximum normalized BSA area was removed from the whole blood at the final 
measurement point (Y=42 mm).  Again, this measurement was predicted within 0.5% 
using a COMSOL simulation.    These experiments validated the COMSOL model used 
to simulate the mixing of soluble species in each of the fluid streams.  Line scans of FITC 
dye and BSA at each position illustrated the mixing of these two tracers (Figure 5-3).  
The order of magnitude difference in their diffusion coefficients explains the disparity 
[108, 109]. 
After the model was validated, it was used to simulate the minimum concentration 
of Ca2+ in the citrated whole blood along the length of the channel (Figure 5-1G).  The 
wall shear rate controlled the minimum Ca2+ concentration by decreasing the time the 
fluid remained in the channel (tf).  A 30 mM Ca
2+ buffer solution provided a maximum 
centerline concentration of 20 mM Ca2+.  At a wall shear rate of 600 s-1, a minimum Ca2+ 
concentration of 9 mM was reached prior to the first patterned collagen/TF surface.  This 
Ca2+ concentration was sufficient to recover a free calcium concentration equivalent to 
CTI blood [112]. 
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Figure 5-1 A trifurcated microfluidic device to recalcify citrated whole blood 
under flow. 
A trifurcation microfluidic device was designed to recalcify citrated whole blood prior to 
contact with patterned collagen ± TF surfaces (A).  Citrated whole blood was sheathed 
with 30 mM calcium buffer (µ=3 cP) at the entrance of the trifurcation design (B).  The 
sharp gradients between the buffer and blood were illustrated, at the entrance, using FITC 
dye (C).  The calcium gradients at the trifurcation entrance were simulated using 
COMSOL (D).  The normalized FITC dye (E) and BSA (F) area were measured and 
simulated in the middle 100 µm of the channel at discrete points along the channel 
(depicted in A).  Minimum calcium concentrations in the middle 100 µm of the channel 
were simulated in COMSOL for wall shear rates ranging from 200 s-1 to 2000 s-1 (G).  
Fluid transit times (tf) along the length of the channel were calculated for each shear rate. 
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Figure 5-2 Whole blood sheathed in buffer experienced a constant wall shear 
rate. 
COMSOL was used to calculate wall shear rate across the 300 µm trifurcation channel.  
In the blood region or the middle 100 µm of the channel, the wall shear rate remained 
constant.  Alternatively, the buffer regions experienced shear rate gradients due to corner 
effects.  Constant wall shear rates experienced by the blood region mimic in vivo injuries 
where cylindrical vessels remove corner effects. 
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Figure 5-3 FITC and BSA line scans within the trifurcation channel. 
Line scans of FITC fluorescence intensity (A) and Texas Red BSA fluorescence intensity 
(B) were averaged across the trifurcation channel.  Measurements were made at eight 
locations beginning at the trifurcation point (0 mm).  At a wall shear rate of 600 s-1, FITC 
dye diffusion progressed rapidly along the length of the channel.  Conversely, channel 
transit times limited protein diffusion (BSA). 
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5.3.2 Recalcification of citrated whole blood under flow recovers platelet and 
coagulation function 
Citrated whole blood was sheathed with 30 mM Ca2+ buffer at a wall shear rate of 
600 s-1.  Collagen/TF was patterned at a distance of 6 mm downstream from the 
trifurcation entrance.  Platelet (red) and fibrin(ogen) (green) accumulation were measured 
dynamically at the 250 μm patterned surface (Figure 5-4).  After 4.2 min of flow, platelet 
aggregation was evident while fibrin(ogen) was not (Figure 5-4A).  Following an 
additional 3 min of flow, fibrin(ogen) accumulated  at the downstream portions of the 
clot in areas free of platelets (Figure 5-4B).  Platelet and coagulation activity continued 
to increase after 10 min of flow (Figure 5-4C).  The constant shear gradient generated in 
the trifurcation device removed the corner effects observed during full channel flow 
(Figure 5-5). 
In order to demonstrate proper recalcification, platelet and coagulation function 
were measured by perfusing whole blood anticoagulated with CTI and citrate with and 
without calcium in the sheath buffer (Figure 5-6).  Collagen/TF surfaces were patterned 
at 7 positions along the length of the channel.  Platelet and fibrin(ogen) fluorescence 
intensities were measured at each localized injury site (L=250 m, W=100 μm).  Both 
platelet and fibrin(ogen) accumulation required Ca2+ in the sheath buffer.  Platelet 
aggregation with recalcification buffer began after 6 minutes of flow (Figure 5-6A).  
Similar platelet fluorescence intensities were not reached until 15 minutes without 
recalcification buffer (Figure 5-6B).  On average, final platelet fluorescence intensities 
were reduced by 87.3 ± 9.3% when Ca2+ was absent.  Fibrin(ogen) accumulated shortly 
after platelet aggregation in the recalcification experiment (Figure 5-6C).  In the 
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experiment without Ca2+, fibrin(ogen) accumulation was completely abolished yielding a 
reduction of 99.0 ± 0.9% (Figure 5-6D).  When the [Ca2+] was calculated to be >16 mM 
in the blood, the fibrin(ogen) fluorescence intensity remained stable.  Interestingly, this 
was the same concentration where the difference between the time to 25% of the 
maximum fluorescence intensity (fibrin(ogen) t25% - platelet t25%) reached a global 
minimum (Δt25%=0.2 min).  These studies demonstrated the dependence of recalcification 
buffer for proper platelet and coagulation function on patterned collagen/TF surfaces. 
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Figure 5-4 Whole blood recalcified under flow recovers platelet and coagulation 
function. 
A strip of collagen/TF was patterned downstream (Y=6 mm) of the trifurcation entrance.  
Citrated whole blood was recalcified under flow (600 s-1) with 30 mM Ca2+ buffer.  
Platelet (red) and fibrin(ogen) (green) accumulated at the localized injury site, illustrated 
at the 4.2 min (A), 7.3 min (B), and 10.4 min (C) time points. 
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Figure 5-5 Buffer sheath flows eliminate corner effects on clot formation. 
Line scans of normalized platelet and fibrin(ogen) fluorescence intensity were averaged 
at a patterned collagen strip (250 µm) for full channel flow (A) and buffer sheathed flow 
(B).  The full channel flow illustrated the effects of wall shear rate dropping to zero.  
Both platelets and fibrin(ogen) accumulate in the corners (0 µm and 250  µm).  The 
buffer sheathed flow yielded maximum platelet and fibrin(ogen) accumulation near the 
center of the flow. 
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Figure 5-6 Recalcification is required for proper platelet and coagulation 
function. 
Whole blood anti-coagulated with both CTI and citrate was sheathed in buffer (µ=3 cP) ± 
30 mM Ca2+.  Blood and buffer ± Ca2+ were perfused (600 s-1) across seven, equally 
spaced, 250 µm collagen/TF strips each identified by the distance in millimeters from the 
entrance of the channel.  Dynamic measurements were collected for both platelet (A-B) 
and fibrin(ogen) deposition (C-D) at each location. 
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5.3.3 Intrinsic generation of factor XIIa primed platelet and coagulation activity in 
citrated whole blood 
The addition of CTI to whole blood provided selective inhibition of factor XIIa 
[113].  This impedes the initiation of the intrinsic pathway.  Citrated whole blood alone 
does not prevent the generation of factor XIIa because factor XII is activated 
independently of calcium [114].  The effect of factor XIIa on platelet and coagulation 
activity were investigated by measuring platelet and fibrin(ogen) accumulation on a 
collagen/TF surface (Y= 6 mm) with citrated blood incubated for 5 min or 30 min after 
phlebotomy.  Platelet aggregation initiated 5 min faster when citrated whole blood was 
incubated for 30 min rather than 5 min (Figure 5-7A).  Final platelet aggregation, 
measured by final fluorescence intensity, was increased by 159%.  Likewise, after a 30 
min incubation fibrin(ogen) accumulation initiated 2 min faster with an 86.6% increase in 
final fluorescence intensity (Figure 5-7B).  Measurements made with citrated whole 
blood incubated for 5 min were similar to measurements made with whole blood 
anticoagulated with CTI and citrate.  The extra incubation time (25 min) facilitated the 
generation of factor XIIa.  This primed the intrinsic pathway resulting in accelerated 
platelet and fibrin(ogen) accumulation at the injury site upon recalcification. 
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Figure 5-7 Incubation of citrated whole blood primed platelet and coagulation 
activity via factor XIIa. 
Citrated whole blood was incubated for either tincubation=5 min or tincubation=30 min 
following phlebotomy.  A 30 mM Ca2+ buffer sheathed and recalcified the citrated whole 
blood prior to the collagen/TF strip (Y= 6 mm).  Platelet (A) and fibrin(ogen) (B) 
deposition was measured and compared for both incubation times.  
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5.3.4 Single channel IC50 measurement of MRS-2179 under flow 
Whole blood anticoagulated with PPACK (a potent thrombin inhibitor) was 
perfused through the trifurcation device.  Buffer with a physiologic calcium concentration 
(2.4 mM) was used to sheath the blood along the length of the channel.  The % 
hematocrit of the whole blood was calculated at each patterned collagen surface (Figure 
5-8A).  As the blood travelled down the channel the red blood cells dispersed and the % 
hematocrit dropped slowly.  At the final collagen strip the % hematocrit was reduced by 
~13% (assuming an initial % hematocrit of 45%).  After the % hematocrit dropped below 
38%, the platelet deposition decreased significantly (Figure 5-8B).  While boundary 
depletion may not be excluded, this effect was not observed in studies with CTI and/or 
citrate.  The presence of thrombin in those studies may have masked any observable 
platelet depletion. 
In a related experiment, we investigated the effect of MRS-2179 (a platelet P2Y1 
antagonist) on platelet deposition.  The 2.4 mM Ca2+ buffer was supplemented with 10 
μM MRS-2179 and platelet fluorescence intensity was measured at 8 collagen strips 
downstream of the trifurcation entrance.  The MRS-2179 drastically reduced platelet 
fluorescence intensity at all 8 positions as compared to buffer without MRS-2179 (Figure 
5-8B).  The % platelet inhibition was calculated at each position and compared to the 
simulated [MRS-2179] along the length of the channel (Figure 5-8C).  The calculated 
IC50 (0.155 μM) compares favorably to previous IC50 measurements made under flow 
conditions (0.173 μM) [70].  The length of the channel used in this design made it 
possible to study MRS-2179 concentrations varying over an order of magnitude.  This 
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facilitated accurate measurements of an IC50 value below 1 µM.  The trifurcation device 
used in this study is the first device capable of measuring platelet antagonist IC50 values 
with a single channel.  It is also the first device to accomplish these measurements using 
automated mixing to achieve a range of concentrations. 
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Figure 5-8 Single channel IC50 measurement. 
The % hematocrit of whole blood sheathed with buffer was measured in the middle 100 
µm of the channel along the entire length (A).  A 2.4 mM Ca2+ buffer ± 10 µM MRS-
2179 (platelet receptor P2Y1 antagonist) was used to sheath PPACK whole blood prior to 
collagen exposure.  Platelet deposition was measured at eight evenly spaced collagen 
strips for buffer with and without MRS-2179 (B).  % Platelet inhibition and predicted 
MRS-2179 concentration were determined along the length of the channel (C). 
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5.4 Discussion 
The laminar flows (Re ~1) found in microfluidic devices make convective mixing 
extremely difficult.  Often times this characteristic mixing time is a limitation of 
microfluidic devices that can only be altered by the addition of active or passive mixers 
[115].  Rather than working against this limitation, we used long channel lengths to take 
advantage of diffusional mixing.  We designed a trifurcation microfluidic device that 
utilizes differences in species diffusion coefficients to reach varying levels of 
concentrations along the length of a channel.  Previous work with trifurcation designs 
have focused on concentrating or separating cells by utilizing acoustics and dextran/red 
blood cell affinities respectively [116, 117].  Instead, our work exploited the differences 
in protein and small molecule diffusion rates to recalcify or antagonize human whole 
blood under flow.  This is the first reported device to recalcify citrated whole blood and 
measure platelet IC50 values under flow conditions without premixed concentrations of 
Ca2+ or antagonist in whole blood.   Recalcification of citrated whole blood and mixing of 
platelet antagonist under flow minimizes user error in measurements that may have 
clinical implications. 
Platelet and coagulation assays currently adopted by clinicians use blood products 
primarily anticoagulated with sodium citrate [101, 102].  The main advantage of using 
citrated blood is the increased storage time and control of the initiation time 
(recalcification).  Standard assays such as the aPTT and PT both use citrated blood but 
neither incorporate flow.  These tests are forced to extrapolate their data in an attempt to 
understand how clotting occurs under flow.  The device described here not only 
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incorporates flow but it also provides a measurement for both platelet and coagulation 
function.  In addition, recalcification under flow maintains a constant initiation time that 
eliminates the generation of activated coagulation factors prior to exposure of the 
collagen/TF surface.  This feature provides repeatable recalcification of citrated blood 
without the need of an expert technician.  Along with proper recalcification, the designed 
device allows for single channel IC50 measurements.  Platelet or coagulation antagonist 
IC50 values can be measured at submicromolar accuracy as demonstrated by our MRS-
2179 measurement.  This approach may be useful for future designs that desire 
personalized drug dosing. 
The implications of this device are not limited to citrated blood recalcification and 
platelet IC50 measurements.  This device also recreates constant wall shear stress injuries 
as experienced by injured cylindrical vessels in vivo.  Corner effects in rectangular 
microfluidic devices cause gradients in wall shear stress that facilitate platelet adhesion to 
collagen during whole blood perfusion [31].  Removing this shear gradient eliminates 
lower shear zones where platelets and coagulation factors accumulate.  Instead, as 
platelets accumulate at a constant wall shear stress they are forced to generate their own 
zones of lower shear stress to facilitate coagulation factor accumulation and fibrin 
generation.  This represents a scenario experienced by an injury in vivo.  In the future, 
studying the intrinsic and extrinsic generation of fibrin at constant wall shear stress might 
help distinguish their dependence on platelets at higher and lower shear stresses. 
While solute diffusion was the primary means of investigation for this study, the 
length and mixing properties of this device make it a valuable tool for control of 
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temperature, pH, and hematocrit levels in future work.  Investigating the effects of 
temperature (hypothermia), pH (acidosis), and hematocrit on platelet and coagulation 
function make this device suitable for studying the varying levels of trauma [118].  
Current assays such as thromboelastometry overestimate the integrity of coagulation 
under varying combinations of these symptoms which make new assays desirable [119].  
This device also has the ability to determine the influence of erythrocyte aggregation, a 
typical consequence of trauma [120], on clot formation.  While red blood cell aggregation 
[121], and deformability has been studied in sepsis models [122], this system would 
permit further investigation on their roles in thrombosis and hemostasis.  There have been 
very few microfluidic devices developed for addressing the severity of these symptoms 
and the effects on platelet and coagulation function.  Using this device to investigate 
these symptoms in varying combinations could reveal new insights for the treatment and 
diagnosis of patients experiencing trauma. 
5.4 Conclusions 
We have demonstrated the design and novel implications of a device to rapidly 
recalcify citrated whole blood and dose anti-platelet drugs using buffer sheath flows.  
Whole blood anticoagulated with sodium citrate was recalcified under flow with buffer 
sheath flows containing Ca2+.  COMSOL simulations and measurements of 
platelet/fibrin(ogen) deposition with and without Ca2+ in the sheath buffer confirmed that 
recalcification was completed prior to being exposed to patterned collagen/TF surfaces 
downstream.  The addition of CTI to citrated whole blood prevented the priming of the 
intrinsic coagulation protein XIIa when blood was incubated for 30 min after 
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phlebotomy.  The long channel lengths used in this design enabled IC50 measurements 
for the platelet antagonist MRS-2179.  Measurements made agreed with previously 
reported values which illustrates the devices submicromolar accuracy.  The designed 
device provides a unique platform for studying constant wall shear stress injuries 
following whole blood recalcification or platelet inhibition under flow. 
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Chapter 6 : Future Work 
6.1 Effect of platelet contraction on clot growth 
The device designed in Chapter 2 has the ability to study the architecture of clots 
developed under physiologic conditions, as illustrated in Chapter 4.  Our work in Chapter 
4 defined both physical and biological conditions in which thrombin mediated clot 
growth was regulated.  Another important aspect of clot development, which was only 
briefly addressed in Chapter 4, is the ability of the clot to contract.  Clot contraction has 
an important role in preventing blood loss and anchoring the clot to the injury site to 
prevent embolism [59, 123].  In vivo results have implicated that clot consolidation via 
contraction aids in retaining solutes by decreasing their transport within the architecture 
of the clot [75].  Interestingly, human platelets are larger than mouse platelets [124].  This 
property may change the role of platelet contraction in human blood clots. 
In order to investigate the role of clot contraction on the resulting clot 
architecture, we performed a preliminary set of experiments in the absence and presence 
of 10 µM blebbistatin, a potent myosin IIa inhibitor (Figure 6-1) [68].  Whole blood 
anticoagulated with CTI was perfused across a collagen/TF scaffold as previously 
described in Chapters 2-4.  The wall shear rate was set at 400 s-1 and the transthrombus 
pressure gradient was maintained at 20 mm Hg.  Total clot, fibrin, and P-selectin positive 
area were dynamically calculated throughout the experiment.  The total clot area of clots 
treated with blebbistatin grew to a greater extent (1.48-fold, P<0.01) than control clots 
(Figure 6-1A).  Their initial clot area remained unchanged until 6 min of growth 
(P<0.05).  The fibrin area did not significantly change in the presence of blebbistatin 
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(Figure 6-1B).   % P-selectin positive area was significantly delayed (t=1.5 min, 
P<0.025) and reduced (15.1%, P<0.05) when clot contraction was inhibited (Figure 
6-1C).   
These results indicate that clot contraction is important for clot consolidation as 
evident by the increase in total clot area in the presence of blebbistatin.  The impact on 
thrombin generation and localization is less clear.  The fibrin polymerization data 
supports a claim that thrombin removal may not have been increased because the total 
fibrin area remained constant.  In contrast, the delay in % P-selectin area and decrease in 
final % P-selectin positive area may have been a result of decreased thrombin retention.  
In order to determine the role of clot contraction, several additional experiments will need 
to be performed.  As with our work in Chapter 4, the clot architecture will need to be 
examined at both venous and arterial shear rates to determine the role of clot contraction.  
The different platelet packing and fibrin densities could drastically influence platelet 
contraction.  In addition, the thrombin sensor will need to be used to determine the 
localization of thrombin within the resulting clots.  This will describe the presence of 
thrombin in greater detail then the fibrin polymerization results.  It may also be beneficial 
to increase the concentration of blebbistatin to 100 µM.  Previous literature has 
demonstrated different effects of blebbistatin at 10 µM and 100 µM [68].  These 
experiments are required to decipher the role that clot contraction has on thrombin 
mediated clot growth in human blood clots. 
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Figure 6-1 Clot contraction reduces total clot height and increases the % P-
selectin positive area of the clot. 
Clot growth was investigated during 10.5 min of CTI whole blood perfusion (400 s-1) 
over a collagen/TF scaffold.  Whole blood was treated with buffer or 10 µM blebbistatin 
prior to perfusion.  Total platelet area (A) and fibrin area (B) were calculated using a 
fluorescently conjugated, platelet or fibrin specific antibodies respectively.  % P-selectin 
positive area, as defined by a P-selectin antibody, was calculated based on the P-selectin 
positive area and total clot area for both conditions (C). 
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6.2 Model for evaluating the effect of inflammation on clotting 
Throughout Chapters 2-4 we have described a microfluidic device capable of 
studying clot growth and architecture at controlled wall shear rates and transthrombus 
pressure gradients.  While this device excels in models of hemostasis and thrombosis, it 
may also be appropriate for studying the inflammatory response, an additional phase of 
wound healing.  To date, there are very few in vitro models capable of studying the 
interaction of flow developed blood clots and neutrophils.  Neutrophils are migratory 
leukocytes that respond to bacterial infection at the site of injuries in a process known as 
chemotaxis [125].  Their migration towards the infected area is controlled by chemokines 
such as TNF-α and IL-8 [126, 127].  Lipopolysaccharides (LPS), an endotoxin located on 
gram-negative bacteria also has a prominent role in initiating the immune response.  LPS 
is known to cause a response in both platelets and neutrophils.  The toll-like receptors 
(TLR-4) on platelets facilitate a response to LPS resulting in increased platelet binding to 
fibrinogen and neutrophil extracellular trap (NET) activation [128, 129].  NET’s are 
composed of chromatin fibers and have been implicated in increased DVT risk due to 
elevated thrombin generation [130].  In addition, LPS can also cause other white blood 
cells to release chemokines to attract neutrophils to the site of bacterial infection [131].  
Understanding the migratory and NET releasing response of neutrophils, at the site of 
injury, may be a valuable tool for advancing patient care, specifically in DVT and sepsis.  
Our preliminary investigations into neutrophil migration (Figure 6-2) and LPS 
induced activation of platelets and neutrophils (Figure 6-3) were performed in the device 
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we designed and outlined in Chapter 2.  Interestingly, our first observation of neutrophil 
migration came when we observed a white blood cell migrating across a developed clot 
while studying clot permeability.  In this study we perfused CTI whole blood (1000 s-1) 
over a collagen/TF surface with a transthrombus pressure gradient of 20 mm Hg.  After 
~14 min of flow we turned a valve to change the whole blood to buffer to visualize the 
fluorescent pulse travel through the permeable structure.  Throughout the experiment, we 
followed the migration of an adhered leukocyte (Figure 6-2A).  The distance the 
leukocyte travelled remained relatively unchanged throughout the buffer pulse (Figure 
6-2B).  In contrast, there was an obvious change in distance from the starting point when 
the buffer pulse was perfused through the clot (Figure 6-2C).  Prior to the buffer, the 
leukocyte travelled in a distinct manor towards the collagen/TF scaffold.  As the whole 
blood transitioned to buffer (t=14 min), the direction of movement dissipated with the 
leukocyte moving in a stochastic manner.  As the blood flow was reestablished (t=20 
min), the leukocyte began to migrate towards and into the collagen scaffold (Figure 
6-2A).  These results lead to a hypothesis that leukocyte chemotaxis requires plasma, in 
the absence of endothelial cells.  To further investigate this process, several experiments 
would need to be performed.  First, the system may need to be modified to recruit 
additional leukocytes to the injury site.  This could be accomplished by reducing the 
shear rate to a venous shear rate or by adding chemoattractants such as TNF-α and IL-8 
to the collagen/TF scaffold.  Second, the modified system could be used to observe the 
migration of multiple leukocytes while whole blood was transitioned to buffer or whole 
blood.  Finally, inhibiting proteases (cathepsin G or α-chymotrypsin) or receptors (fMLP 
or Fc) responsible for leukocyte chemotaxis could help to define which proteases or 
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receptors are required for this process [132, 133].  These experiments could be used to 
determine which components of plasma are responsible for directing leukocyte migration. 
The other inflammatory response that we investigated was the LPS induced 
activation of platelets and neutrophils at the site of an injury (Figure 6-3).  In this 
preliminary experiment, we perfused CTI whole blood (100 s-1) across a collagen/TF 
(Figure 6-3A) or a collagen/TF/LPS scaffold (Figure 6-3B).  Average clot height 
(Figure 6-3C) and clot associated neutrophil counts (Figure 6-3D) were calculated 
throughout the duration of the experiment.  Platelets were imaged with fluorescently 
conjugated CD41 antibodies and neutrophils were imaged with fluorescently labelled 
CD18 antibodies.  Interestingly, the clot formed on the collagen/TF/LPS scaffold grew 
2.3-fold larger than the clot formed on the collagen/TF scaffold.  The growth of the clots 
did not begin to differentiate until after 4 min of flow.  At this time, clot growth remained 
constant on the scaffold with LPS while clot growth on the scaffold free of LPS began to 
dissipate.  The delay in growth rate changes may be due to the increase in clot associated 
neutrophils (27-fold more) in the clot formed on the LPS scaffold.  Future experiments 
will need to be performed to evaluate the effect of LPS on both platelets and neutrophils.  
In order to determine the effect of LPS independently on platelets, we will inhibit 
neutrophil activation with proepithelin (PEPI) and secretory leukocyte protease inhibitor 
(SLPI) [134].  This will allow us to study clot formation dependent solely on LPS without 
the influence of activated neutrophils.  In addition to these studies, we will also add 
antibodies for P-selectin expression and thrombin activity.  These markers will provide 
insight into the regulation of thrombin in clots formed in the presence of LPS.  Finally, 
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NET formation and influence on clot structure will be studied with Sytox green staining.  
These measurements will provide information regarding the influence of NET formation 
on platelet recruitment and thrombin generation.  Further investigations of neutrophil 
migration and interactions with developing clots will be important for understanding the 
mechanisms of clot formation in patients at risk for DVT and sepsis.  Moving forward, 
we will be able to use the device that we developed and characterized in Chapters 2-4 to 
study the inflammation stage of wound healing under physiologic conditions.   
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Figure 6-2 Plasma perfusion through blood clots is required for white blood cell 
chemotaxis towards the injury site. 
CTI whole blood was perfused across a collagen/TF scaffold at 1000 s-1 for ~14 min.  
Following clot development, buffer was pulsed through the system (14 min-20 min) 
before whole blood was reestablished.  A white blood cell (green) was tracked throughout 
the growth of the clot and the pulse of buffer (A).  The total distance the white blood cell 
travelled (B) and the distance the white blood cell moved from the starting point (C) were 
tracked throughout the experiment.    
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Figure 6-3 LPS embedded in a collagen/TF scaffold induces larger clot growth at 
venous shear rates. 
Whole blood anticoagulated with CTI was perfused at the venous shear rate of 100 s-1 
over a collagen/TF scaffold in the absence (A) or presence (B) of 100 pg/mL LPS.  
Average clot height was calculated in both conditions using a platelet specific 
monoclonal antibody (C).  Average clot associated neutrophil count was estimated by 
using a fluorescently conjugated CD18 antibody to calculate total neutrophil area.  This 
area was divided by the average area of a neutrophil based on diameter. 
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